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Abstract 
Amyloid forming peptides and proteins present an extreme challenge for modern analytical 
measurement techniques. When natively-folded biomolecules partition into misfolded forms, 
they produce a myriad of inherently unstable conformations that eventually lead to the presumed 
cytotoxic species linked to disease. Most often, these cytotoxic states take the form of small 
oligomeric species that exist within a complex mixture of other oligomers that may, or may not, 
be related to a disease etiology. In addition, these dynamically-generated oligomers are present 
in small amounts, within a complex mixture of other biomolecules, small molecules, and metal 
ions that may also influence the ensemble of states being measured. Ion mobility separation, 
coupled to mass spectrometry, has recently become a key technology for the analysis of amyloid-
forming peptides and proteins due to its ability to analyze low concentrations of complex 
mixtures. Described here is the application of IM-MS to study protein interactions with small 
molecules, dipeptides, and neuropeptides. This combine information furthers the knowledge base 
of neurodegenerative diseases from a structural standpoint. 
First, the interaction of amyloid beta: leucine enkephalin was discovered in a screen of many 
neuropeptides. This interaction was characterized using IM-MS through collision cross section 
and Kd measurements. Multiple copies of leucine enkephalin are found to bind with amyloid 
beta, each with an approximate binding strength of 60 micromolar. Modeling suggests binding 
near the structured core region of amyloid beta. Following these initial studies, site directed 
amino acid substitution of leucine enkephalin reveals that the hydrophobic C-terminal residues 
phenylalanine and leucine are critical for binding to occur. Alanine substitutions of amyloid beta 
residues, selected based on simulated annealing results, indicate residues Y10 and Q15 to be 
most critical for the interaction of amyloid beta with the dipeptide FL. Molecular dynamics 
models were filtered using IM-MS experimental results, and structures representative of the 
interaction are shown. Additionally, workflow to study amyloid beta has been applied to the 
oligomerization of ubiquitin monomer and linear tri-ubiqutin in the presence of copper ions, 
measuring an increase in the number of dimeric species. Stability measurements using collision 
induced unfolding, and aggregation propensity of Ubiquilin2 are also studied.   
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Chapter 1.  
Introduction 
Amyloid forming peptides and proteins present an extreme challenge for modern analytical 
measurement techniques. When natively-folded biomolecules partition into misfolded forms, 
they produce a myriad of inherently unstable conformations that eventually lead to the presumed 
cytotoxic species linked to diseases such as Alzheimer’s and Parkinson’s Disease. Most often, 
these cytotoxic states take the form of small oligomeric species that exist within a complex 
mixture of other oligomers that may, or may not, be related to a disease etiology. In addition, 
these dynamically-generated oligomers are present in small amounts, within a complex mixture 
of other biolmolecules, small molecules, and metal ions that may also influence the ensemble of 
states being measured. All of these factors conspire to create an exceedingly complex mixture, 
within which the conformational, oligomeric, and molecular composition of a single targeted, 
disease-associated species is typically sought. As such, separative tools, capable of portioning 
such a complex mixture in the context of both molecular shape and identity, are required to 
completely evaluate the molecular mechanisms involved in biomolecular amyloid formation.  
Ion mobility (IM) separation, coupled to mass spectrometry (MS), has recently become a key 
technology for the analysis of amyloid-forming peptides and proteins. The general concept of IM 
involves the measurement of gas phase ion migration rate or trajectory in the presence of both an 
electric field and a drag force to analytes such that larger ions possess longer migration times, or 
altered trajectories, compared to smaller ions of equal molecular mass. Additionally, ions 
possessing greater charge can be separated from those with lower levels through the same 
combination of forces. By virtue of the charging mechanisms operative in electrospray ionization 
(ESI), protein oligomers often have mass -to- charge (m/z) values identical to protein monomers, 
making the size and charge separation afforded by IM essential in analyzing MS data acquired 
for amyloidogenic systems. Described here is the detail of IM-MS methodology as applied to 
disease associated protein aggregation systems.
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 1.1. Amyloid in Human Disease 
Proteins which are unable to remain correctly folded, or which do not fold correctly lead to 
biological malfunction and many diseases1. These misfolded proteins can aggregate and interact 
with cellular components, potentially causing cell death. Amyloidoses are a specific group of 
protein folding disease, where specific proteins misfold and aggregate leading to extracellular 
amyloid deposits, made up of highly organized β-sheets2. Diseases in this class include, but are 
not limited to Alzheimer’s, Huntington’s, systemic amyloidosis, type II diabetes and 
Parkinson’s3, 4.Aggregation can occur when a protein never folds to the correct structure or it is 
unable to maintain the fold. This may be due to a mutation in protein sequence, interaction with 
metals, changes in pH or temperature, and even chemical modification5, 6. Figure 1.1 below 
Figure 1.1. Overview of the possible states accessed by a protein which leaves its native fold. This includes 
degradation of the unstructured protein, or disordered aggregate formation which may or may not be on 
disease pathway. Some disordered aggregates form an equilibrium with β-structured aggregates which go on 
to form amyloid fibrils.    
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highlights the pathways available to a protein which leaves its native fold. The when the 
equilibrium shifts between the native fold and a partially unfolded form, cellular processes 
should assist in the degradation of the unfolded protein. However if the abundance achieves a 
certain threshold the protein moves towards nucleation of β-structured aggregates which grow 
into fibrils.  
The amyloid hypothesis suggests a causative link between protein deposits and pathological 
symptoms of disease3, 4, 7 and has been widely accepted. However, experimental data now 
suggests the most toxic species to the cell is actually pre-fibrillar aggregates. This has been 
demonstrated with Amyloid β (Aβ), α synuclein and transthyretin8-13.  It is thought that the 
misfolding of the protein allows hydrophobic residues, which would be buried in the native state, 
to interact with membranes or cellular components14, causing toxicity. Additionally, the channel 
hypothesis has been proposed [131]. This suggests that aggregates in a pore structure may 
interact and insert into lipid membranes with cytotoxic results5, 15, 16.        
1.1.1. Alzheimer’s Disease and Amyloid β 
Of all forms of dementia, it is thought that 50-60% of all cases are Alzheimer’s Disease (AD)17, 
18. AD symptoms include memory loss, cognitive decline, and is the sixth leading cause of death 
in the US19-21. Three are currently three hypotheses on the pathogenesis of AD 1) the metal ion 
hypothesis22-26, 2) the amyloid cascade hypothesis19, 20, 27 and 3) the oxidative stress hypothesis28-
30. The metal ion hypothesis suggests AD is caused through impaired metal ion homeostasis (Zn, 
Cu and Fe) with the end result being Aβ imbalance24, 25. By the oxidative stress hypothesis, age, 
genetics, or environment enhances oxidative stress, causing gene defects and mitochondrial 
function to decline28, 31, 32. As the target of this thesis, the amyloid cascade hypothesis is briefly 
summarized below.  
A non-amyloidogenic cleavage of the amyloid precursor protein (APP) occurs at residue 687 
with α-Secretase. This happens within the Aβ formation region and thus prevents its formation. 
Pathogenic Aβ is formed from β-secretase and γ-secretase cleavage of APP at residues 672 and 
710-714 respectively, and so, is traditionally 39-43 residues long33, 34. The most abundant from 
of Aβ is 40 amino acids while the most pathogenic form is 4233, 35, 36. Once formed Aβ can 
produce soluble oligomers, protofibrils, or extracellular aggregates. As discussed previously it is 
thought that the extracellular aggregates are not directly toxic, but rather the soluble oligomers 
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and protofibrils cause cell death37-39. It is thought that Aβ1-42 is more toxic than Aβ1-40 because 
the two additional hydrophobic amino acids36, 40, 41. Pathogenicity is theorized to occur in one of 
several ways. The first is that Aβ oligomers directly damage the neurons and cause cell death42, 
43. Second, formation of membrane-soluble channels destroy electrochemical signaling44-46. 
Lastly it is possible Aβ disrupts the respiratory chain within the mitochondria causing oxidative 
stress34, 47, 48.       
1.2. Ion Mobility Mass Spectrometry for Protein Aggregation Determination 
IM is a gas phase separation technique that shares a similar operation principle with the solid and 
solution phase electrophoresis methods typically applied by biochemists. The combination of IM 
and MS instrumentation provides additional advantages realized in the analysis of oligomeric 
mixtures. Such experiments typically begin with ESI, which charges protein oligomer ions 
according to their overall surface area. In this context, all protein ion populations occupy a range 
Figure 1.2 – General Schematic of the Synapt HDSM quadrupole-ion mobility-time-of-flight mass 
spectrometry instruments used here. A) Complete instrument diagrams shown with the four main regions of 
the instrument: ion generation with nESI source, ion selection in the quadrupole mass analyzer (capable of 
selecting up to 8,000 m/z in the Synapt HDMS, and modified to select up to 32,000 m/z in the Synapt HDMS 
G2), ion mobility separation (detailed in B and C), and ion mass analysis using a time of flight mass 
analyzer. B) Detailed ion mobility separation, tri-wave region, of the Syanpt HDMS and C) tri-wave region 
of the Synapt HDMS G2. The tri-wave region includes three T-wave ion guides the ion trap (blue), ion 
mobility cell (purple), and transfer (yellow-green) regions. The HDMS G2 is additionally equipped with a He 
cell (orange) to assist with transition across the pressure gradient with minimal ion activation. Typical 
pressures associated with the regions are indicated.  
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of charge states, and those generated for the monomer will inherently overlap with the dimer, 
creating some m/z signals that are a composite of multiple oligomer states. IM separates ions 
based on their CCS (CCS, a rotationally averaged size measurement), and charge. For monomers 
and oligomers possessing an overlapping m/z ratio, these properties will differ. As such IM is a 
critical tool to decouple the influence of oligomers which could not be separated based on MS 
alone49, 50. Work presented in this thesis was completed on one of two IM-MS platforms by 
Waters (Milford, MA): the Synapt HDMS or the Synapt G2 HDMS. The platforms are both 
equipped in a similar fashion, as diagramed below (Figure 1.2), with a nanoelectrospray (nESI) 
ionization source, a quadrupole mass analyzer, travelling-wave ion mobility separator (IMS), and 
Time of Flight (TOF) mass analyzer. Variation between platforms includes a high m/z 
quadrupole and a helium gate at the entrance to the IMS on the Synapt G2, in addition to 
different detectors. The high mass quadrupole allows for the selection of larger proteins and their 
oligomers, while the helium gate lowers the center of mass energy of collisions for injection into 
the IM separator. The lower energy means more labile structures will survive the injection.   
1.2.1. Ion Generation 
To analyze samples using IM-MS, one must first transition sample into the gas phase while 
simultaneously charging the analyte. Two ion sources common in biological MS experiments 
have been used to analyze the content and composition of amyloidogenic peptides and proteins. 
The most common of the two being electrospray ionization or its nano form. This technology 
directly converts solution-phase protein at low micromolar concentrations into gas-phase ions by 
aerosolizing the sample into micrometer-nanometer scale droplets, desolvating those droplets to 
reveal naked protein ions, and charging these proteins in a manner highly correlated with their 
solvent accessible surface areas51. nESI can generate a desolvated structure on the nanosecond 
time scale with concomitant cooling from the loss of water52. The speed and cooling effects of 
ESI allow for the capture of solution phase equilibria with regards to oligomeric and structural 
populations in aggregating systems. The mechanisms of ESI are described below. In contrast 
Matrix-Assisted Laser Desorption Ionization (MALDI), provides more circuitous routes between 
the native state and gas-phase ions, such as requirement of a matrix, and the ions are typically 
singly charged. The matrix is added in solution, and the water allowed to evaporate forming a 
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solid around the protein ion, which may alter solution phase structure. For these reasons 
therefore not generally preferred over ESI53, 54. 
Two models for ion formation using electrospray ionization have been proposed. The first, the 
charged residue mechanism, proposes ion generation through evaporation and Coulombic 
fission55-57 and is mostly widely accepted for the ionization of large molecules. After emission 
from the electrostatically charged capillary tip (1-4kV)58 droplets undergo evaporation, and the 
droplet diameter decreases until charges within become too crowded. At this point, the “Rayleigh 
limit”, Coulombic repulsion breaks surface tension of the droplet and fission occurs. The process 
is repeated until the analyte has become completely desolvated, “naked”, leaving the charges 
deposited on the surface of the protein, or protein complex. (Figure 1.3). In a similar, but 
distinctly different mechanism, the Ion Evaporation Model59, before the protein has become 
completely desolvated, the charges of the protein and the other charges in the droplet cause 
ejection of the analyte into the gas phase. This mechanism is more accepted for small molecules. 
Figure 1.3 – Diagram of the mechanism of electrospray ionization (ESI) where A) diagrams the 
relative position of the conductive capillary needle with analyte solution near the entrance of the mass 
spectrometer. B) When high voltage is applied to the capillary and entrance, a Taylor cone is formed 
generating highly charged droplets which experience evaporation reducing their diameter. Protein 
molecules are charged primarily through the CRM in C) where droplets undergo evaporation 
followed by a series of droplet fission events until only charged protein remains. Alternatively, 
smaller proteins may undergo IEM shown in D) where, as the droplet evaporates the electric field 
increases, forcing the analyte to the surface where it evaporates off, taking charge from the droplet as 
it leaves.   
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Likely a combination of the two is in effect60, especially when analyzing a complex mixture of 
proteins and/or peptides with small molecules.  
1.2.2. Protein Transmission, Mass Analysis and Detection 
The hybridization of a quadrupole mass filter and orthogonal ToF analyzer has allowed for an in 
depth analysis of intact macromolecular complexes not accessible by other technologies. These 
macromolecular complexes however, come with an increased challenge. To more easily transmit 
large ions two parameters can be manipulated.  First, pressures may be adjusted by adding 
collision gas or reduce pumping in various places through the flight path of the ions61 . Second, 
one can use a flow restricting sleeve to increase the pressure of the first ion guide62. This 
‘collisionally cools’ the trajectories of the ions by dampening their radial velocity and better 
guides them to the detector62. While collisional cooling of most protein aggregating systems is 
not necessary due to their small monomer size, to see large oligomers or to conduct studies on 
disordered proteins of a larger size, this method may be of advantage. 
A quadrupole mass analyzer, is built from four parallel rods which are positioned equidistantly 
from the center-axis of the instrument63, 64. Paired rods are placed opposite one another. One pair 
is applied with a direct current (DC) and the other radio frequency (RF) voltages. In the first pair, 
the DC voltage is the same for each rod. For the other pair RF voltage oscillates at the same 
frequency, but opposite magnitude. Due to the field created, ions with a single m/z are 
transmitted through to the detector. Operation can be performed in single ion monitoring mode, 
or in a scanning mode with both DC and RF voltages applied. Turning the quadrupole to RF-
only mode (DC voltage = 0) operates the devices as an ion guide and allows a wide range of m/z 
ions to pass through the field making the technique optimal for continuous ion sources.  
In contrast to the four rod geometry of the quadruople, ToF mass spectrometers65, 66 are made up 
of three regions: an ion pusher, a flight tube, and a detector. By nature of the ion pusher, ToF is a 
pulsed technique and can be suitably coupled to fast separations. A packet of ions are pushed 
into the flight tube with specific kinetic energy. Ions with equivalent charge have equivalent 
energy, and ions of higher charge have higher energy. Once in the flight tube, ions that are more 
massive or lower charged will travel through the flight tube at a slower velocity while lighter or 
higher charged ions will travel faster, due to kinetic energy being directly proportional both mass 
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and velocity. The time it takes ions to travel the flight tube and be recorded by the detector can 
then be converted into m/z, giving this mass analyzer an unlimited m/z range.     
1.2.3. IM Separation   
The theoretical basis for measuring the mobility of ions in the gas phase was first described by 
Langevin in 190367.Work presented by Bradbury in 193168 applied this theoretical work to 
measure the mobility of ions in the gas phase. By modifying previously established methods69, 70 
of introducing pulsed packets of ions, Bradbury was able to compare the mobility of both 
negatively, and positively charged ions. Although this early work lacked the sensitivity to 
measure minor differences in mobility, it would lay the corner stone for modern instruments with 
resolutions capable of distinguishing smaller changes in ion size.  
Figure 1.4 – Drift Cell Ion Mobility Separation. Ions are introduced into the mobility separator at a 
defined start time. Ions traverse the drift cell under the influence of a uniform weak electric field. 
Separation then occurs under the influence of a constant number density of a neutral backing gas (e.g., He 
or N2). A) Given two proteins with same relative charge, the small compact protein will traverse the cell 
unimpeded and exit rapidly, larger ions due to their extended conformational state will interact with the 
backing gas more often and therefore exit later. B) When separating ions of the same m/z (i.e., 
monomern+ and dimer2n+), ions with the increased level of charge will traverse the cell faster due to the 
increased influence of the static field on higher charge states.    
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Arguably the simplest form of IM instrumentation is the drift tube. This equipment separates 
ions, within a pulsed packet, according to their mobility through a pressurized (1-1000 mBar) 
drift cell in the presence of an axial electric field71. All ions experience the same electric field, 
and the time to traverse the drift cell is measured. Ion drift times can be easily converted to CCS, 
defined as a rotationally averaged ion-neutral interaction potential72, 73. The velocity of an ion, 
under the influence of the superimposed electric field is also proportional to its charge72, 74, 
therefore, any ion with a lower CCS (Figure 1.4A), or higher absolute charge (Figure 1.4B)71, 75, 
will exit the drift cell before a large, lower-charged ion. Ion CCS is also weakly correlated to 
molecular mass, resulting in apparent ‘trend-lines’ on a plot of IM drift time versus m/z for 
different molecular classes that display similar packing densities in the gas-phase. For example, 
peptide ions typically have a higher packing density than lipids of equivalent molecular mass, 
but do not typically create ions of greater gas-phase densities than nucleotides (i.e., Lipid CCS > 
Peptide CCS > Nucleotide CCS). Within a given molecular class, detailed CCS measurements 
can provide further anti-correlations with respect to molecular mass, further weakening the 
general correlation discussed above and providing increased orthogonality between IM and mass 
spectrometry (MS) measurements76-80. By measuring the drift time of a defined ion population 
iteratively over many different axial electric field strengths, drift tube IM instruments can record 
the mobility of an ion, and thus its CCS, to a high degree of precision and accuracy if the 
experimental conditions are known81. The experimental conditions accounted for in such a 
calculation include: the mass and density of the buffer gas, the operating temperature and 
pressure of the drift cell, as well as an accurate calculation of the ion’s mass and charge49, 74, 82. 
To accurately assess the analyte mass and charge required to complete the CCS calculations, the 
drift cell is most often coupled to a MS analyzer (Figure 1.5). The first example of combined IM-
MS instrumentation, capable of both drift time and m/z measurements, was described in 196283. 
This instrumentation was used for the study of ion-molecule reaction kinetics, and it was not 
until 1989 that such equipment was applied to obtain ion geometry and reactivity information84, 
85. In addition to the IM drift cell previously described, two further variations on the mobility 
separator have been applied to the study of amyloidogenic proteins and protein complexes. These 
are the travelling wave, and high field 
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 asymmetric ion mobility separators86-88. The travelling wave technique, extensively used in this 
work, is expanded upon below. 
The travelling wave ion guide, or T-wave, separates ions based on their differential mobilities 
under the influence of a direct current (DC) voltage wave originating within a stacked ring ion 
guide. This non-uniform voltage traverses the stacked-ring ion guide through the sequential 
application of a DC voltage to neighboring electrodes, forming a voltage wave along the axial 
plane of the device. As this travelling voltage wave traverses the guide, analyte ions are 
propelled by the wave, and collide with a neutral gas during transit through the device. Ions with 
larger CCS exhibit an increased number of collisions, slowing their migration when compared to 
more compact ions with the same molecular mass. Due to this increased collision frequency, 
large CCS ions are more likely to pass over the crest of multiple wave fronts during their transit 
Figure 1.5 – IM separation combined with ToF MS to create a multi-dimensional separation and 
analysis tool. Within the IM component ions are initially separated according to their CCS and 
charge on the millisecond time scale. Following is mass analysis  within the ToF mass analyzer, 
occurring on the microsecond time scale allowing for the rapid deconvolution of mass spectra, by 
separating conformational and oligomeric families with overlapping m/z values.   
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through the device. As with the drift 
tube device described above, the 
absolute charge adopted by an ion 
also represents a key factor in T-
wave IM separation, with ions of 
increased charge repelled by the 
voltage wave more strongly and 
will therefore exhibit decreased 
migration times89, 90.  
Compared to drift tube IM, the T-
wave exhibits a more complex 
relationship between measured drift 
time and CCS. While drift tube IM 
possess a direct relationship 
between drift time and CCS, the T-
wave exhibits an exponential 
relationship between these two 
values, which varies between 0.2 
and 0.8 under typical experimental 
conditions. This exponential 
relationship results in a T-wave 
CCS axis that is elongated and 
expanded relative to the migration 
times measured in the device. In addition, because the functional form of the relationship 
between IM migration time and ion size varies substantially in T-wave separators, data acquired 
using this method are typically calibrated in order to generate accurate CCS values for unknown 
ions. In contrast, these calibrations are not required in drift tube IM if all the relevant 
experimental variables are known. Additionally, peak resolution (t/∆t) in drift tube IM depends 
only upon the voltage differential applied to the device and the temperature of the experiment, 
whereas T-wave IM resolution is influenced by the properties of the waves used to propel the 
Figure 1.6 – Travelling Wave Ion Mobility Separator. The T-wave 
mobility separator differs from the drift cell by A) using a non-
uniform voltage distribution across the length of the cell to separate 
ions as a result of a DC voltage applied to individual electrodes of 
alternating the alternating Rf stacked ring ion guide. Voltage is 
applied to sequential electrode producing a ‘travelling wave’. 
Repulsion between the polarity differences of the wave and analyte, 
propels ions through the mobility separator. As ions ride the crest 
of the DC wave more conformationally extend B) and lower 
charged C) ions undergo increased interactions with the backing 
gas and are more likely to pass over the crest, exiting the T-wave 
later.     
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ions (e.g. frequency) and exhibits a direct correlation to the mobility of the ions analyzed73, 75, 91, 
92. 
Calibration of T-wave drift time data requires strict control over the travelling wave parameters 
used to separate ions. Calibration of travelling wave data uses known CCS values for a series of 
calibrant ions, measured originally on drift tube IM analyzers50, 92-103. Using the exponential 
formalism described briefly above, under controlled instrument conditions, a calibration curve 
can be constructed to generate T-wave CCS values for a broad range of biomolecular ions73, 104, 
105. The calibrants selected for this procedure should have drift times that bracket those of the 
unknown, to reduce errors that result from extrapolation of the data points91, 92, 94, 104. Using these 
calibration techniques, a high level of reproducibility, precision and accuracy in T-wave CCS 
values can be achieved106. Most T-wave CCS values are normalized to drift tube CCS values 
recorded in helium in order to enable detailed computational analyses; however, T-wave drift 
times are typically recorded in nitrogen to maximize resolving power and T-wave instrument 
performance. While such conversions impart negligible errors for large protein ion CCS values, 
these errors become increasingly significant for small molecule and peptide T-wave CCS 
values92, 93. 
1.2.4. Collision Induced Unfolding 
Beyond the measurement of CCS, IM-MS can measure protein structure transitions in the gas-
phase through collision induced unfolding (CIU)107-109. In a typical CIU experiment ions of a 
single charge state are first selected in the quadrupole mass filter. Upon entry into the trap t-wave 
the ion population is activated via collisions with argon. Voltages in the trap region are raised to 
increase the energy of the collisions (typical range = 20-200 V). Drift time of the ion population 
is measured at each trap voltage, capturing partially-folded intermediate states which are unique 
to the gas phase110. A plot of the drift times vs voltage, with intensity on the z-axis create a CIU 
fingerprint111. The energy at which the intermediately unfolded conformations appear can be 
related back to stability of the protein112, 113. 
1.3. Modeling Protein Interactions with Experimental CCS 
IM-MS analysis, through the measurement of accurate CCS values for amyloid forming peptides 
and proteins, enables the production of models that closely estimate the observed gas phase 
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structural populations. In order for the CCS measurements recorded to be used effectively in the 
model building process, they must be accurate and precise. In order for the resulting models to be 
useful for elucidating the biologically-relevant mechanisms of amyloid formation, measurements 
must have a strong correlation with the solution phase conformations114. Recent MS, IM-MS, 
spectroscopic, and molecular modeling experiments have revealed much regarding the correlated 
nature of native and gas-phase protein structure. Following protein desolvation on the nano to 
pico second time scale, hydrogen bond and van der Waals interactions on the protein surface can 
be destabilized to result in side chain re-arrangements and compactions that are broadly uniform 
across all protein structural families. For highly-charged proteins, Coulombic repulsion can 
result in protein remodeling and unfolding, promoting the formation of a range of gas-phase 
conformers that likely bear little resemblance to those found in solution52, 114-116. Protein ions 
having a sufficiently low charge state do not typically undergo such Coulmbically-mediated 
distortions and retain compact configurations in the gas-phase that are stable on the millisecond 
timescale, and can be easily correlated to X-ray and NMR datasets. Such correlations have 
extended from monomeric proteins to larger hetero-protein complexes, including a range of 
topologies, architectures, and structures. As IM-MS experiments are run on the millisecond 
timescale, and since net protein charge is a critical factor in the gas phase stability of ions, 
exceeding a system-dependent threshold allows the native-like gas-phase state of the protein to 
unfold52, 115, 117. 
1.3.1. Molecular Dynamics Simulations   
Direct comparisons between IM-MS derived CCS values and high-resolution structure data 
requires computational methods aimed at building and refining models, as well as algorithms 
designed to simulate IM separation and calculate theoretical CCS values for in silico models in 
order to compare with experimental data. Coarse-grain modeling approaches may assist in the 
building of multimer models. For example, oligomers of Amyloid β118 and β2-microglobulin119 
have been analyzed by building spherical models of growth, ranging from globular to linear, then 
matched to experimental collision cross sections to determine the best fit model114, 120. In 
addition to coarse-grain models, detailed structures of protein misfolding disease systems have 
been collected using two main kinds of molecular dynamics simulations: simulated annealing 
and replica exchange molecular dynamics121-124. Of the two, simulated annealing is the less 
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computationally exhaustive, and simpler approach. A protein sequence in the simulation is 
heated to high temperatures, unfolding the structure within the computational space, followed by 
a temperature decrease that allows the protein to refold. This temperature oscillation is repeated 
multiple times, allowing the protein to escape any local energy minima and adopt an energy-
minimized structure. Replica exchange molecular dynamics is similar to the simulated annealing 
method, in that a protein is heated in silico to remove it from local minima in the energy 
landscape. The key difference is that rather than ramping the temperature on one coordinate set 
at a time, several replicas are run in parallel each starting at different temperature points. 
Throughout the run, the proteins are exchanged from one temperature level to another. This more 
effectively samples the energy landscape accessed by molecular dynamics than simulated 
annealing does, but results in a more computationally-intensive modeling workflow. 
1.3.2. Theoretical CCS Calculation Techniques 
For IM-MS studies of amyloidogenic proteins, four methods have been applied to convert in 
silico models into theoretical CCS values for comparison with experimental data. These methods 
are: the trajectory method (TM)125, projection approximation (PA)125, exact hard sphere 
scattering (EHSS)126, and projection superposition approximation (PSA)127-130. These methods all 
differ according to the level of projected interaction complexity calculated between the backing 
gas and analyte structure undergoing ion mobility separation, correlating strongly with the 
computational demands required to perform them. The PA represents the least computationally 
demanding algorithm, as it calculates only the rotationally averaged CCS117, 131 using Monte 
Carlo scoring127. This method is known to underestimate the CCS however, which has been 
supported by experimental observations using the T-wave ion mobility separator125, 131. In 
contrast the TM represents the most accurate method for calculating CCS data from structural 
models131, accounting for all the direct and indirect interactions between the analyte and neutral 
backing gas as well as their collision geometries (i.e. angle of deflection)125. By accounting for 
these interactions, the TM represents a computationally intensive method, thereby limiting its 
application for studying larger complexes. 
Compared to the PA, both the EHSS and PSA approaches represent gains in calculated CCS 
accuracy, while remaining computationally inexpensive compared to the TM. The EHSS 
improves computational efficiency by removing the long range electrostatic interaction 
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calculations calculated by the TM, which account for an accuracy difference of only a few 
percent between the two, but often drastically over-estimates the experimental CCS of proteins 
and peptides125, 131, 132. Comparatively the PSA combines the basics of the PA model, with buffer 
gas/analyte size and distance dependent collision probabilities that replace the idea of hard 
interactions between the two127. This method has been shown to provide improved agreement 
between experimental and calculated CCS data, while promoting a tenfold increase in 
computational speed compared to the TM129. Finally, appropriately-scaled versions of PA CCS 
estimates have also been used to accurately relate X-ray and NMR datasets to IM-MS120. 
1.3.3. Other Experimental Data Used to Refine Models 
IM-MS is a dynamic tool, useful in the elucidation of protein mass and size, However, IM-MS 
data alone is often not enough to generate a complete model of amyloidogenic protein structure. 
In much of the literature, IM-MS results are presented in combination with other techniques such 
as NMR, X-ray crystallography, transmission electron microscopy (TEM, described in detail 
below), and gel electrophoresis. NMR and X-ray crystallography, in contrast to IM-MS, provide 
higher resolution of the protein structure, however they require more material at a higher 
purification, and are unable to measure ensembles of structural states and binding 
stoichiometries. Thus in combination with IM-MS, these technologies allow access to a more 
complete picture of the structural populations.  
In addition, other MS-based tools such as hydrogen/deuterium exchange (HDX), oxidative foot 
printing, and chemical cross-linking coupled to MS detection can provide structural information. 
Combined with CCS and other biophysical data, these methods can provide a robust integrated 
framework from which to filter potential structural models for amyloid-forming peptides and 
proteins. In general, integrated structural biology workflows allow for an expanded analysis of 
protein oligomerization and interaction pathways as well as a method to validate nascent 
functional hypotheses.  
In TEM imaging a thin layer of sample is irradiated with an electron beam. This electron beam is 
focused using electromagnetic lenses and passes through the sample. Electrons are scattered 
based on sample density. Any unscattered electrons hit a fluorescent screen. This produces an 
image of the sample, where darker areas represent a higher density due to increased scattering133. 
This tool is highly useful in the study of formed amyloid fibrils134, 135.  Site directed amino acid 
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substitution and other chemical modification experiments can also supplement primary IM-MS 
data to better evaluate hypotheses. Frequently in the context of amyloidogenic peptide and 
protein datasets, the biologically relevant mutant forms of the wild type (WT) protein are 
studied, as in the case of the familial mutations of Amyloid β (Aβ)136. Such experiments allow 
for the assessment of disease relevant complexes relative to similar WT data, analyzing 
aggregation pathways and structures in both a relative and absolute fashion. 
Alternatively, directed amino acid substitutions, targeted to a specific interaction site or region of 
structural importance suggested by previous IM-MS data, can serve as a control data set in 
evaluating and filtering available structural models. Such experiments are typically accomplished 
by altering a residue to prevent the protein from acting in its normal fashion, such as inhibition of 
random coil to β-sheet fibrils of Aβ by the F19P mutation or oxidation of methionine at residue 
Figure 1.7 – Workflow applying IM-MS to protein misfolding diseases. Interactions of aggregates, protein-protein, 
protein-peptide, and protein-small molecule can be studied with IM-MS, providing information on CCS and 
determination of stoichiometries formed. Using a ratio of intensities, binding strength to a specific protein 
conformation can also be calculated. Following IM-MS experiments, molecular dynamics simulations can be 
performed and results are filtered by experimental data. Site directed amino acid substitution experiments using IM-
MS can also provide further information when compared to WT data. By combining all the data available, the 
analysis results in both a population of potential structures and putative mechanisms for protein fibrillation.  
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35118, 137. In addition to altering specific residues within a protein, IM-MS experiments regularly 
compare sequence variants and isoforms of the same protein to probe for structural information. 
The most common example of this is the Aβ peptide which encodes 39-42 amino acid 
residues118, 138. It has also 
been shown with the 
comparison of aggregation 
prone human islet amyloid 
polypeptide (IAPP) with the 
rat variant, which does not 
form amyloidogenic fibrils139, 
and two structural isoforms of 
the Syrian hamster prion 
protein fragment (90-231)140.  
1.4. Relevant Examples 
and Literature 
Highlights 
IM-MS can be applied in 
many ways to study the 
pathway of protein 
misfolding, oligomerization, 
and fibril formation6. Three 
major areas of current IM-MS 
study in this general area are: 
1) assessing the conversion of 
natively-structured 
monomeric proteins into 
partially unfolded, disease-
associated forms, 2) 
monitoring the transition 
between disordered 
Figure 1.8 – Within the protein misfolding pathway, IM-MS has been applied 
to partially unfolded proteins, disordered and β-structured aggregates, as well 
as protein oligomers. A) Three monomeric subunits of β2-microglobulin were 
studied at varying pH. The solid black line represents a compact growth 
model for the oligomers. Compared with these compact theoretical structures 
the experimental data for the dimer, D, trimer, T, and tetramer, Q, have CCS 
values indicating elongated structures, along the dashed line. B) Drift time 
data Aβ1-40 and Aβ1-42 at the -5/2 charge state show vastly different 
populations of oligomer structure as an effect of the two amino acid 
difference on the c-terminal. C) Upon collisional heating of a protein 
complex, subunits may dissociate from one another or begin to unfold. In the 
Transthyretin data shown here, both events are observed at various stages of 
unfolding and monomeric subunit dissociation. These levels of unfolding and 
dissociation are strongly correlated to the charge state of the parent ion.    
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aggregates and β-structured aggregates, 3) the characterization of larger oligomer populations 
formed in vitro for isolated amyloidogenic peptides and proteins. (Figure 1.86, 107, 118, 119) 
Examples of amyloidogenic systems where IM-MS has been previously applied over the course 
of multiple studies include β2-microglobulin (β2m, implicated in haemodialysis related 
amyloidosis)119, IAPP (linked to the disease progression in type II diabetes)124, Aβ peptides and 
fragments (implicated in or connected to Alzheimer’s Disease)118, α-Synuclein (implicated in 
Parkinsons’s Disease)141 and Prion protein (associated with Spongiform encephalopathies)142. In 
addition, a Tetrameric Transthyretin (TTR, implicated in familial amyloid neuropathy and senile 
systemic amyloidosis)107, ataxin-3 (implicated in Spinocerebellar ataxias)143, Alpha 1-antitrypsin 
(implicated in Serpinopathies)144, and Tau (implicated in Alzheimer’s Disease)145. While not 
intended to be comprehensive, the literature overview presented below is designed to highlight 
relevant papers which have advanced the study of protein misfolding diseases using IM-MS.  
1.4.1. Amyloid β 
As one of the most studied sequences associated with a protein misfolding disease, Aβ represents 
an ideal introduction to IM-MS studies in protein aggregation as both the protein interactions 
with itself, small molecules, and other neuropeptides have been explored. Methods such as 
modelling, solution phase NMR, X-ray crystallography, and TEM in support of acquired IM-MS 
data have been employed to answer questions about the Aβ peptide and oligomers. 
Drift tube IM-MS data has been reported for many forms of Aβ, and these experiments have 
revealed much in terms of the structure and olgomerization mechanism for this class of peptides. 
In addition to studies of the WT Aβ40 and Aβ42 peptides118, 138, 146, experiments have 
incorporated the Aβ42 Pro19 alloform137, Met35(O) of both the Aβ40 and Aβ42118, in addition to 
Familial Alzheimer’s disease mutations136 and fragments of Aβ encoding residues 21-30147, 148 
and 39-42149. For example, data in 1.7B, shows a drift time distribution comparison of WT Aβ40 
and WT Aβ42 labeled as the -5/2 charge state (meaning the -5 charge state of the dimeric form of 
the peptide or larger charge states for larger, even-numbered oligomers that overlap in m/z)118. 
Identified WT Aβ42 oligomer species include monomers, dimers, tetramers, hexamers, and 
dodecamers. In contrast WT Aβ40 lacks the hexameric and dodecameric species of the more 
toxic Aβ42, showing only the dimer and a more compact tetramer. Using a combination of IM 
and modeling comparisons, data suggests that the two additional C-terminal amino acid residues 
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found in Aβ42 promotes a conformation difference in lower order oligomers, predominantly 
within the tetramer. Compared to the Aβ40 species, Aβ42 produces less compact tetramers, and 
it is these that are suggested to allow the formation of the potentially toxic hexameric paranuclei. 
These paranuclei are subsequently required to produce the toxic dodecameric oligomer species 
that allow rapid fibril formation in WT Aβ42. In the absence of these paranuclei, Aβ40 fibril 
formation is comparatively slower. Mutations that affect the structure of oligomers, can 
additionally limit the formation of higher order oligomers. Highlighted examples include the 
mutations F19P Aβ42, as well as Met35(O) in both Aβ40 and 42118, 137.          
While the above work presented evidence of only even number oligomers, additional IM-MS 
data have identified a trimeric Aβ40 species at a high concentration of 200µM150. This work 
further identified oligomers of masses equal to 16 monomeric subunits in compact as well as 
extended conformations. The differences between this oligomerization pathway, and the IM-MS 
data for even-numbered oligomers discussed above is likely promoted by a number of factors 
common in Aβ research. For example, sample preparation, instrument conditions, ionization 
sources, and protein concentration all vary substantially between these studies, all potentially 
leading to altered Aβ oligomerization rate and pathway.  
In addition to understanding the mechanisms of isolated Aβ aggregation, IM-MS has begun to 
emerge as a technique to study the effect of ligand binding on the structure and stabilities of both 
aggregates and their precursor proteins. On emerging area for study is the interaction between 
Aβ and other proteins, peptides, and small molecules that might further elucidate the aggregation 
mechanism of the peptide, and also serve as a foundation for the discovery of new 
biotherapeutics. For example, several IM-MS datasets have been reported regarding the 
interactions (-)-epigallocatechin-3-gallate (EGCG), a known small molecule inhibitor of amyloid 
fibril inhibition, with the Aβ peptides Aβ40, Aβ42, and Aβ(25-35)121, 151. Other small molecule 
inhibitors of Aβ studied using IM-MS include Scyllo-inositol151, Z-Phe-Ala-
diazomethylketone152, and Diphenylpropynone (appendix III)153. In many instances, the small 
molecules are also studied in conjunction with the presence or absence of metal ions such as zinc 
and copper121, 153, 154. IM-MS data provides information on the altered oligomerization pathway 
upon binding of one or more of the small molecules, based on the oligomer stoichiometry and 
size observed.  
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Beyond the assessment of small molecule-Aβ complexes, IM-MS data has been used to 
characterize small peptide fragments in terms of their binding site, strength, and structure when 
in complex with Aβ peptides (see chapter 2). WT Aβ has been shown to interact directly with its 
C-terminal fragment Aβ(39-42) using IM-MS, and complex formation further leads to an altered 
aggregation pathway, but not the inhibition of fibril formation149, 155.  Additionally the Aβ(25-35) 
fragment has been shown to interact with Tau(273-284), again, reducing fibril formation of Aβ 
but not abolishing it. However interactions increased the ability for Tau monomers and dimers to 
aggregate156. 
1.4.2. β2-microgloublin  
While many of the studies discussed above focus on the aggregates formed by amyloidogenic 
peptides such as Aβ, early IM-MS experiments on β2m focused on the structure and dynamics of 
the monomeric form (Figure 1.8A). High field asymmetric ion mobility spectrometry (FAIMS) 
and T-wave IM data have been used to analyze the structural forms of β2m that evolve as a 
function of solution pH, and these data have been linked to solution-phase biophysical 
measurements under similar conditions88, 157, 158. Three different conformer populations were 
found as a function of pH: the natively folded population at pH 6.0-4.5, a partially folded form at 
pH 4.5, and a completely unfolded state at pH values less than 3.5. The pH dependence detected 
in IM-MS data agrees well with data produced with other biophysical studies on isolated β2m 
folding. In addition to the monomeric population, IM-MS detected β2m oligomers up to and 
including the tetramer119. Subunit exchange within these oligomers was monitored using 14N- 
and 15N- labelled oligomers to follow the incorporation dynamics of equivalent monomers under 
equilibrium conditions.  Compared to monomers and dimers, the trimer and tetramer exhibited 
decreases in subunit exchange kinetics, indicating that larger β2m oligomers possess increased 
stability. IM-MS experiments have also been used to screen β2m interactions with small 
molecule therapeutics, enabling tests of such compounds to both stabilize protein conformations 
and oligomers that prevent the formation of cytotoxic species and full-length amyloid. These in 
vitro studies indicated that the mycobacterium-focused antibiotic Rifamycin SV could potentially 
be repurposed for treatment of haemodialysis related amyloidosis, and acts to bind specific 
conformers of β2m in solution, although other ansamycin-type antibiotics screened appeared less 
effective at halting aggregation and amyloid formation159, 160. 
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1.4.3. Islet Amyloid Polypeptide/ amylin 
IAPP has been studied in depth at the monomeric and dimeric level by IM-MS and replica 
exchange molecular dynamics simulations123, 124. IM-MS has been used, for example, to compare 
the structures of human IAPP (hIAPP) to the non-amyloidogenic rat IAPP (rIAPP)139, 161. In the 
hIAPP monomer, two conformational families were observed and assigned to a β-hairpin family 
and a more compact helix-coil family using molecular dynamics simulations. Two pieces of 
evidence point to the β-hairpin conformation family as the amyloidogenic structure: 1) rIAPP 
does not adopt this conformational family under the experimental conditions probed, and 2) 
acidic pH values, which are correlated with increased rate of amyloid fibrillation, promote an 
increased population of this structure in hIAPP124. The dimeric species of hIAPP exhibits a more 
extended conformation in comparison to rIAPP dimer123 supporting the notion that β-hairpin 
monomers are necessary to build β-sheet multimers. 
Additional studies analyzed murine amylin using integrated data from TEM, AFM, x-ray 
diffraction, IM-MS and chemical cross-linking assays to study higher order oligomeric 
conformations of the peptide161. In addition to the monomeric and dimeric species identified 
previously, more recent studies have identified oligomer sizes up to and including hexamers for 
both hIAPP and rIAPP in vitro. While both peptides exhibited the expected elongated 
conformations described above, hIAPP appeared to possess increased structural stability when 
compared with rIAPP analogs139. Similar to the screens described above for Aβ and β2m, IM-
MS data has identified two small molecule inhibitors of amylin fibril formation, the natural 
products EGCG and silibinin, that might lead to a deeper understanding of the role hIAPP plays 
within type II diabetes139. With robotically assisted screening, new methods of high throughput 
inhibitor identification has become possible162, 163. 
1.4.4. α-synuclein 
IM-MS data reported for α-synuclein indicate that, although natively unstructured, its ensemble 
of structural states is dependent upon solution pH141. Surprisingly, the protein adopts a more 
compact structure at pH 2.5 than observed at pH 7. A detailed analysis of these data indicated 
that this effect relates specifically to the charge the protein carries in the gas-phase, especially 
when charges are located within its C-terminal region. When the protein possesses eight or less 
negative charges it adopts a compact structure; when a ninth charge is added the protein 
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extends141. IM-MS has been used to study two disease relevant mutations of α-synuclein: A53T 
and A30P164. Similarly to the WT, A53T IM-MS indicated a compact structure for the -6, -7, and 
-8 charge states of the protein. In contrast to WT, the A30P only exhibits a compact state while 
occupying the -6 charge state. Spermine binding to all three variants caused charge reduction and 
structural compaction and increased aggregation originating from the collapsed monomer 
populations164. Additionally, low concentrations of autoproteolytic fragments were observed by 
IM-MS between residues 72-140, increasing the propensity of the protein to form aggregates165. 
1.4.5. Prion Protein 
Syrian hamster protein protein (SHaPrP) is a model system that has been studied by both drift 
tube and T-wave IM-MS140, 142, 166. Two structural isoforms were analyzed at pH 5.5 and pH 7.0; 
the α-helical construct, and the β-sheet-rich form of SHaPrP(90-231). Interestingly, at pH 5.5 
there was a measureable difference in arrival time distributions recorded for these two prion 
isoforms, where the α-helical isoform exhibited a smaller CCS than the β-sheet form. At pH 7 
however, these differences were not apparent166. Other work has applied IM-MS toward CCS 
measurements of both monomers and higher order PrP(106-126) oligomers in combination with 
replica exchange molecular dynamics142. β-hairpin monomers are suggested to be important in 
the oligomerization of PrP142. 
1.4.6. Other Amyloidogenic Peptides and Proteins 
In addition to the proteins discussed previously, there are a number of proteins associated with 
protein misfolding disease and aggregation that have been studied by IM-MS, including: TTR107, 
Alpha 1-Antitrypsin144, 167, Insulin94, Ataxin-3143, and Tau145, 156. For example, in addition to 
forming misfolded states and large oligomers that are disease-associated, TTR forms a native 
homo-tetramer, which distinguishes this system from other amyloidogenic proteins studied to 
date by IM-MS (1.7C). WT and disease associated TTR (L55P) have been tested for their 
stability while bound to the natural TTR ligand, thyroxin107. The stability assay used, based on 
IM-MS is termed collision induced unfolding (CIU) and uses energetic collisions with 
background gas to heat protein ions and initiate their unfolding in the gas-phase. While distinct 
from other MS tools, the methodology utilizes much of the same formalisms discussed in the 
collision induced dissociation of proteins and multi-protein complexes168, 169. In the example of 
TTR, the variant protein was stabilized to a greater extent by thyroxin binding than the WT TTR 
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in a manner only observable by the CIU assay107. Similar CIU assays are currently being 
deployed to search for conformationally selective inhibitors and resolve subtle tertiary structure 
differences that are inaccessible by standard IM-MS technology81. As such, CIU will likely be 
deployed in the future in a broadened way to screen for inhibitors of protein aggregation.  
1.5. IM-MS as a Drug Screening Technology 
IM-MS cannot currently compete with the speeds of traditional high throughput drug screening 
methods however, it allows for the analysis of target proteins where binding strength 
measurements alone are insufficient81, 162, 163. Amyolid proteins exist in multiple conformational 
states, and polydisperse multiprotein ensembles leading to complex mixtures. IM-MS can allow 
for the detection of small molecules that cause advantageous conformational changes or alter 
oligomeric states in these complex samples. These changes are ones which may not be 
observable with traditional fluorescence screening. Current IM-MS technologies is limited to 
screening hundreds of samples per day due to sample introduction and software available for 
post-acquisition analysis. The clear trade-off is that of information content, IM-MS while slower 
is able to assess changes in oligomeric state, binding stoichiometries, conformational and 
flexibility changes upon ligand binding.      
1.6. Summary 
While a challenge for many analysis techniques, IM-MS provides advantages in the analysis of 
amyloid forming peptides and proteins where others might struggle, such as separating and 
measuring the size of many oligomers in a complex sample. Three IM technologies: drift tube 
and T-wave (with major impact), and FAIMS (with minor impact) have been utilized in the 
analysis of amyloidogenic systems. Using IM-MS experimental results as a filtering tool, coarse 
grain and detailed models of the amyloidogenic systems can be created. Analysis of these models 
through measurement of CCS can be accomplished through the TM, PA, EHSS, or the PSA 
methodologies. IM-MS can be combined with other techniques to refine the models of protein 
aggregation, with these including but not limited to: NMR, X-ray crystallography, TEM, and gel 
electrophoresis. This is in addition to being compatible with a number of MS-based tools to 
further assist in refining the models of aggregation, including: HDX, oxidative foot printing, and 
chemical cross-linking.  
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IM-MS has been applied to many areas of the protein aggregation pathway, including assessment 
of the conversion of natively-structured monomeric proteins into partially unfolded, disease-
associated forms. Furthermore, IM-MS represents a key tool capable of monitoring the transition 
between disordered aggregates and β-structured aggregates, as well as characterizing the early 
steps in the formation of oligomer populations. While the work highlighted here has focused 
mainly on the disease relevant β2m, IAPP, Aβ, α-Synuclein, and Prion protein systems. Other 
examples of IM-MS studies into aggregation prone proteins include TTR, Alpha 1-antitrypsin, 
Insulin, Ataxin-3 and Tau, demonstrating the ever expanding applications of IM-MS. The ability 
of IM-MS to measure structure, and thus stability while unfolding, gives unique advantage for 
use as a screening tool for ligands of the protein misfolding diseases discussed, especially in the 
context of complex mixtures. 
In chapter 2, Aβ is screened for interactions with neuropeptides, and the interaction of Aβ with 
the endogenous opioid neurotransmitter leucine enkephalin is characterized with CCS, Kd, TEM, 
and simulated annealing. (Published, Molly T. Soper, Alaina S. DeToma, Suk-Joon Hyung, 
Mi Hee Lim and Brandon T. Ruotolo (2013) Amyloid-β-neuropeptide interactions assessed 
by ion mobility-mass spectrometry, Phys Chem Chem Phys 15, 8952-8961.)  
In chapter 3, we further characterize the Aβ:LE interaction using site-directed amino acid 
substitutions of LE. It is discovered that the C-terminal residues phenylalanine and leucine are 
critical for the interaction. Interactions of Aβ and the dipeptide FL are explored with site-directed 
amino acid substitutions of Aβ and simulated annealing, discovering Y10 and Q15 to be critical 
for binding. Hierarchical clustering analysis and detailed structures are used model the 
interaction. TEM images show FL inhibits downstream fibril formation. 
In chapter 4, the methodology to study Aβ developed in chapters 2 and 3 is applied to two larger 
protein systems: ubiquitin and the ubiquitin-like ubiquilin2. The aggregation propensity of 
ubiquitin and linear polyubiquitins is studied in the presence of copper. With a 1:1 ratio of 
copper (with respect to number of ubiquitin domains), dimerization occurs with both mono and 
liner tri-ubiquitin. We follow these studies with analysis of ubiquilin2 through comparison of 
WT and P506T variant forms using CIU and measurement of the dimer present.              
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Chapter 2.  
Amyloid β: Neuropeptide Interactions Assessed by Ion Mobility – 
Mass Spectrometry 
Molly T. Soper, Alaina S. DeToma, Suk-Joon Hyung, Mi Hee Lim 
 and Brandon T. Ruotolo (2013) Amyloid-β-neuropeptide interactions assessed by 
ion mobility-mass spectrometry, Phys Chem Chem Phys 15, 8952-8961 
  
Recently, small peptides have been shown to modulate aggregation and toxicity of the amyloid β 
protein (Aβ). As such, these new scaffolds may help discover a new class of biotherapeutics 
useful in the treatment of Alzheimer’s disease. Many of these inhibitory peptide sequences have 
been derived from natural sources or from Aβ itself (e.g. C-terminal Aβ fragments). In addition, 
much earlier work indicates that tachykinins, a broad class of neuropeptides, display 
neurotrophic properties, presumably through direct interactions with either Aβ or its receptors. 
Based on this work, we undertook a limited screen of neuropeptides using ion mobility-mass 
spectrometry to search for similar peptides with direct Aβ binding properties. Our results reveal 
that the neuropeptides leucine enkephalin (LE) and galanin interact with both the monomeric and 
small oligomeric forms of Aβ1-40 to create a range of complexes having diverse stoichiometries, 
while some tachykinins (i.e., substance P) do not. LE interacts with Aβ more strongly than 
galanin, and we utilized ion mobility-mass spectrometry, molecular dynamics simulations, gel 
electrophoresis/Western blot, and transmission electron microscopy to study the influence of this 
peptide on the structure of Aβ monomer, small Aβ oligomers, as well as the eventual formation 
of Aβ fibrils. We find that LE binds selectively within a region of Aβ between its N-terminal tail 
and hydrophobic core. Furthermore, our data indicate that LE modulates fibril generation, 
producing shorter fibrillary aggregates when added in stoichiometric excess relative to Aβ. 
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2.1. Introduction 
Alzheimer’s disease (AD) is currently the sixth leading cause of death worldwide, directly 
affecting over 24 million people globally1. Critically, of the top six causes of death, AD is the 
only cause for which the mortality rate has not decreased over the past 5 years1, 2. There are 
several competing hypotheses describing the onset and etiology of AD3. One of the most 
prominent of these theorems centers on the uncontrolled aggregation of Aβ peptides varying 
from 36-43 amino acids in length, produced from proteolytic cleavage of the amyloid precursor 
protein (APP) in vivo; these Aβ species proceed to form amyloid fibrils or plaques in the brain 
that are comprised primarily of Aβ1-40 and Aβ1-424, 5. While the eventual formation of amyloid 
fibrils serves to demarcate the phenomenology of the disease, and fibrils are found prominently 
in the brains of AD patients, current data suggest that the causative Aβ-related agent, if any, 
takes the form of small oligomers that may range from dimers to dodecamers6-10. Because Aβ 
peptides aggregate both in vivo and in vitro, likely occupying a number of structural and 
oligomeric states simultaneously, the study of Aβ aggregation and its prevention has proven 
challenging for classical structural biology and biophysics tools11.  
A number of small peptides and small peptide fragments have been found to inhibit the 
formation of Aβ fibrils and, in some cases, possess protective or restorative properties with 
respect to the neuronal degeneration that accompanies AD12-17. Such peptides are sought after as 
potential biotherapeutics for AD primarily due to their natural ability to cross membranes and the 
blood-brain barrier18, 19. For example, fragment sequences derived from the C-terminal section of 
Aβ1-42 (C-terminal fragments, CTFs) have been found to directly interact with full-length Aβ 
peptides and inhibit fibril formation and toxicity14. Similarly, proline-rich hydrophobic peptides 
have been found to alter Aβ1-42 folding and fibril formation20. Seminal work in AD indicated that 
tachykinin neuropeptides possess the ability to ameliorate the neurotoxic effects of Aβ 
peptides21. Specifically substance P and physalaemin were found to be inhibitors of Aβ-induced 
neurotoxicity in hippocampal neurons at µM concentrations, whereas other related peptides did 
not display the same abilities. Whether the observed neurotrophic activity of these tachykinin 
peptides is related to their specific roles as neuronal agonists, or if they interact directly with 
soluble forms of Aβ monomers or oligomers is currently unknown. 
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Relatively recently, ion mobility-mass spectrometry (IM-MS) has been used to investigate a 
number of amyloid forming peptides and proteins, providing details on the structures and 
identities of the oligomers formed prior to amyloid fibril formation22, 23. IM separates peptides, 
proteins, and protein complexes according to differences in ion collision cross-section (CCS) and 
charge24. When combined with MS, this technology is a powerful approach to both complex 
mixture analysis25 and for structural studies of heterogeneous biological complexes26. IM-MS 
has been used to identify the oligomers produced by β-microglobulin and transthyretin tetramer, 
23, 27, 28 in the case of the former providing detailed structural and composition information on the 
soluble oligomers formed. Aβ has also been analyzed in detail using IM-MS, revealing much 
regarding the structure of soluble oligomers and the action of potential inhibitors on the fibril 
formation process in vitro. Specifically, IM-MS has been employed to assess the influence of the 
CTF Aβ39-42 on the oligomerization of full length Aβ14. While the addition of CTF to full length 
Aβ did not alter fibril formation, IM-MS showed discrete differences in the oligomerization 
pathway of Aβ when bound to CTF in a manner linked to decreases in Aβ-induced neurotoxicity.  
Inspired both by this previous IM-MS work on CTF-mediated Aβ oligomerization,14 and also the 
earlier work described above relating tachykinin-type neuropeptides to neurotrophic effects in 
neurons doped with excess Aβ,21 we screened a limited panel of neuropeptides for their direct 
interactions with Aβ monomers and small oligomers using IM-MS. While we find no evidence 
of direct interaction between substance P and monomeric/dimeric Aβ1-40, we do detect Aβ 
interactions with leucine enkephalin (LE) and galanin. Of the two neuropeptides, LE displays a 
stronger noncovalent bond (Aβ:LE dissociation constant (Kd) equivalent to Aβ1-40 dimer 
formation), and thus in this work we characterized this complex in detail using IM-MS, 
molecular dynamics (MD) simulations, gel electrophoresis, and transmission electron 
microscopy (TEM). Further analysis of Aβ:galanin interaction is detailed in Appendix 1. 
Concentration dependent doping of Aβ1-40 with LE leads to the formation of peptide oligomers 
having a broad range of stoichiometries, and we find that subsequent LE additions to monomeric 
Aβ are less favored than multiple LE additions to the Aβ dimer. Furthermore, our MD data, 
filtered by CCS values, indicate that the most likely binding site for LE is within the N-terminus 
of the peptide, a region similar to other natural products that have been shown to inhibit Aβ fibril 
formation and neurotoxicity29. Finally, our gel data demonstrate that LE-doped Aβ1-40 samples 
exhibits the increased amount of Aβ species with MW ≤ 25kDa, compared to that observed 
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under LE-untreated conditions. From TEM analysis, mainly truncated fibrillary Aβ are observed 
in contrast to the long amyloid fibrils typically formed by the peptide in isolation. We discuss 
these results in the context of biotherapeutic development for AD, as well as Aβ fibril formation 
in general. 
2.2. Experimental 
2.2.1. General 
Reagents were purchased from commercial sources and used without further purification unless 
specified otherwise. Aβ1-40 was purchased from Anaspec (Fremont, CA, USA). Aβ1-40 was 
dissolved in the supplied 1% (v/v) ammonium hydroxide and diluted with pH 6.9 100mM 
ammonium acetate (Sigma-Aldrich, St. Louis, MO, USA). Peptide concentration for the stock 
solution was calculated from absorbance at 280nm (ε = 1490 M-1 cm-1) using a Thermo 
Scientific Genesys 10UV spectrometer (Vernon Hills, IL, USA) or Agilent 8453 
spectrophotometer (Santa Clara, CA, USA). LE acetate hydrate (YGGFL) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA) and prepared in pH 6.9 100mM ammonium acetate. 
Somatostatin 14, substance P, galanin, and neurotensin were purchased from Anaspec and 
prepared in 100mM ammonium acetate. Sequence identity comparisons between different 
neuropeptides studied here were performed with the LALNVIEW tool, accessed through the 
ExPasy bioinformatics resources30. 
2.2.2. IM-MS 
Mass spectra were collected on a quadrupole-ion mobility-time-of-flight (TOF) mass 
spectrometer (Synapt G2 HDMS, Waters, Milford, MA, USA) with a nano-electrospray 
ionization (nESI) source. Protein ions were generated using a nESI source and optimized to 
allow transmission of noncovalent protein complexes using electrospray capillaries prepared as 
described previously31. Protein complex ions were generated using an aliquot of the sample (ca. 
7 µL) sprayed from the nESI emitter at a capillary voltage of 1.7kV. The source was operated in 
positive ion mode with the sample cone at 50 V. The bias voltage was 45 V, with backing 
pressure at 5.42 mbar and TOF pressure at 7.94 x 10-7 mbar. The travelling-wave IM separator 
was operated at a pressure of approximately 3.0 mbar of nitrogen and helium. Mass spectra were 
39 
 
calibrated externally using a solution of cesium iodide (100 mg mL-1) and analyzed using 
MassLynx 4.1 and Driftscope 2.0 software (Waters, Milford, MA, USA). CCS (Ω) 
measurements were externally calibrated using a database of known values in helium, using 
values for peptides and proteins that bracket the likely CCS and ion mobility values of the 
unknown ions27, 32. We report the standard deviations (σ) from triplicate measurements of CCS, 
but real errors for these values must incorporate the errors involved in the calibration process (an 
additional ± 3%). Samples were prepared by mixing stock solutions (as prepared above) of 
neuropeptide and Aβ1-40 at pH 6.9, to generate a final Aβ1-40 concentration of 20 µM. Samples 
were incubated on ice for 1 h prior to IM-MS analysis.    
2.2.3. Docking Studies 
Flexible ligand docking studies were preformed using AutoDock Vina33. LE was created using 
PyMOL and studies were conducted against the Aβ1-40 monomer (aqueous solution NMR 
structure PDB 2LFM)34. Twenty docking studies, one with each conformation within the PDB 
file, were performed. The structures for LE and Aβ1-40 were prepared for use with AutoDock 
vina using AutoDock Tools33. All hydrogens were added to Aβ1-40 and torsions were kept as the 
default selected in AutoDock Tools. The exhaustiveness for the docking studies was set at 8, 
resulting in 9 output models for each Aβ1-40 conformation. Docked models of LE were visualized 
with Aβ1-40 using PyMOL. 
2.2.4. MD Simulations 
Simulations were started using the minimized Aβ1-40 solution NMR structure (PDB 2LFM)34. 
The simulations were performed using periodic boundary conditions in a dodecahedron with the 
minimum distance between the simulated molecules and the box wall being 1.0 nm. GROMACS 
ligand topology was prepared using the GlycoBioChem PRODRG2 server35. The MD 
simulations were carried out using the GROMACS software package36 and GROMOS96 force 
field37. To constrain the bond length in the Aβ1-40 and LE, the LINCS algorithm was used, 
allowing an integration time step of 2 fs. Long-range electrostatic interactions were treated with 
the particle mesh Ewald method. Temperature was maintained using the method of Berendsen et 
al38. The LE and the Aβ1-40 were separately coupled to external temperature bath with a 
temperature-coupling constant of 0.1 ps.  
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The system was energy-minimized by steepest decent for 500 steps. After equilibration, 
simulated annealing was performed for the Aβ1-40: LE complex in the gas-phase. The three most 
basic Aβ1-40 side chains (R5, K16, and K28) were charged. The system was heated from 300 K to 
500 K over 100 ps, then cooled down to 300 K over the next 100 ps. The cycle was repeated over 
20 ns in order to allow for escape from local minima and enhance equilibration. For the Aβ1-40: 
LE complex, 20 independent simulated annealing runs, each running for a total of 20 ns, were 
performed from the lowest energy complexes generated by AutoDock Vina. From the MD 
trajectory generated, 100 structures were sampled at 300 K and the CCS was calculated with 
Mobcal using the trajectory method algorithm39, 40. Models of the Aβ1-40:LE complexes were 
visualized in PyMOL. In total 2000 structures were generated. Of the 1090 structures which were 
within ± 3% of the experimentally determined CCS, the 201 structures with lowest energy were 
analyzed to determine the Aβ1-40 residues within 4 Å of LE. Standardized values (Z-scores) were 
calculated for each residue of Aβ1-40 and plotted in standard deviation (σ) space in order to 
determine the relative likelihood of LE binding within a given region of Aβ. 
2.2.5. Kd Measurements by MS 
Dissociation constant (Kd) values for the neuropeptides with Aβ1-40 were calculated using the 
relative intensity of each species from the mass spectra, as described previously41. We modified 
this method to accommodate multiple ligand binding events with the following assumptions: (1) 
the spray and detection efficiency of all species are similar, (2) the ligand concentration is 
sufficiently high so that [L]eq remains constant and (3) the ligand binds to the complex one at a 
time in a stepwise fashion. 
For the equilibrium binding of A (unbound protein) and B (a ligand/binding partner): 
𝐴𝐴 + 𝐵𝐵 ↔  𝐶𝐶1 +  𝐶𝐶2 + ⋯+  𝐶𝐶𝑥𝑥   (2.1) 
𝑅𝑅𝑥𝑥 =  [𝐶𝐶𝑥𝑥]𝑒𝑒𝑒𝑒[𝐴𝐴]𝑒𝑒𝑒𝑒      (2.2) 
Where Rx is an equilibrium quotient between the bound form of the protein (Cx, having x ligands 
attached) when interacting with ligand B, and tis unbound for (A). 
[𝐶𝐶𝑥𝑥]𝑒𝑒𝑒𝑒 =  𝑅𝑅𝑥𝑥([𝐴𝐴]0−(∑ [𝐶𝐶𝑖𝑖]𝑒𝑒𝑒𝑒))𝑥𝑥−1𝑖𝑖=11+𝑅𝑅𝑥𝑥     (2.3) 
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Eqn (2.3) above defines Rx for all bound forms of the protein (Ci) and: 
   𝐾𝐾𝑑𝑑𝑥𝑥 =  [𝐶𝐶(𝑥𝑥−1)]𝑒𝑒𝑒𝑒[𝐵𝐵]𝑒𝑒𝑒𝑒[𝐶𝐶𝑥𝑥]𝑒𝑒𝑒𝑒      (2.4) 
Allows for the determination of Kd for any given step in the sequential equilibrium described in 
eqn (2.1), where C0 = A. Standard deviation values (σ) for the Kd measurements reported here 
are shown from three replicate measurements.  
2.2.6. Aβ Aggregation Experiments  
Aβ experiments were performed according to the previously published methods42-49. Prior to 
experiments, Aβ1-40 was dissolved in ammonium hydroxide (NH4OH, 1% v/v, aqueous), 
aliquoted, and lyophilized overnight, and stored at -80 °C. A stock solution of fresh Aβ was 
prepared by dissolving the peptide in 1% NH4OH (10 µL) and diluting with ddH2O. The Aβ 
stock solution was diluted to a final concentration of 25 µM in a buffered solution containing 
ammonium acetate (100 mM, pH 6.9). The Aβ samples were incubated with 0, 1, 3, or 5 equiv. 
LE (1.2 mM stock solution in the same buffered solution) at 37 °C with constant agitation for 
24h. 
Samples from the experiment were analyzed by gel electrophoresis and visualized by Western 
blot using an anti-Aβ antibody (6E10)42-49. Each sample was separated on a 10-20% Tris-tricine 
gel (Invitrogen, Grand Island, NY, USA) and transferred onto a nitrocellulose membrane. The 
nitrocellulose was blocked with bovine serum albumin (BSA, 3% w/v, Sigma, St. Louis, USA) 
containing 0.1% Tween-20 (TBS-T, Sigma) for 2 h at room temperature. Afterward, the 
membrane was incubated with the anti-Aβ antibody 6E10 (1:2000, Covance, Princeton, NJ) in a 
solution of 2% BSA (w/v in TBS-T) overnight at 4 °C. The horseradish peroxidase-conjugated 
goat anti-mouse secondary antibody (1:5000, Cayman Chemical, Ann Arbor, MI, USA) in 2% 
BSA was added for 1 h at room temperature. The Thermo-Scientific SuperSignal West Pico 
Chemiluminescent Substrate was used to visualize the protein bands.  
2.2.7 TEM 
TEM images were taken using Phillips CM-100 transmission electron microscope (Microscopy 
and Image Analysis Laboratory, University of Michigan, MI, USA) using a magnification factor 
of 25 000. Samples for TEM were prepared according to the previously reported methods42-47, 49. 
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Glow-discharged grids (Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, 
USA) were treated with Aβ samples from the in vitro inhibition experiments (5 µL) for 2 min at 
room temperature. Excess sample was removed using filter paper followed by washing with 
ddH2O five times. Each grid was stained with uranyl aceteate (1% w/v ddH2O, 5 µL, 1 min). 
Upon removal of excess uranyl acetate, the grids were dried for 15 min at room temperature.  
2.3. Results 
A limited neuropeptide screen for binding with Aβ1-40 was conducted with five neuropeptides, 
varying in mass and structure. Masses of the neuropeptides in this study ranged from 555.62 Da 
(LE) to 3158.5 Da (galanin). Aβ1-40 prepared for nESI-IM-MS analysis in 100 mM ammonium 
acetate results in a mass spectrum containing both 3+ and 4+ monomer and 5+ dimer ions in high 
relative abundances (Figure 2.1). IM-MS analysis of this same dataset (data not shown) reveals 
evidence of additional oligomeric forms of the monomeric 4+ peptide (vide infra). Aβ1-40-
neuropeptide binding was only detected between Aβ1-40 and two neuropeptides, LE and galanin, 
under our experimental conditions (Figure 2.1). Complex formation between Aβ1-40 and 
Figure 2.1 – Analyses of Aβ1-40 incubated with one equivalent of each neuropeptide by nESI-IM-MS. A) 
Mass spectrum of Aβ1-40 only, with signals corresponding to monomeric and dimeric peptides marked with 
a ‘M’ and ‘D’, respectively. Satellite peaks observed correspond to alkali metal adducts commonly observed 
in nESI-MS. Aβ1-40 was then mixed with equivalent amounts of B) LE (free [M+H]+ at m/z = 556.6), C) 
somatostatin (free [M + 2H]2+ at m/z = 820.5), D) galanin (free [M+3H]3+ at m/z = 1053.8), E) substance P 
(free [M + 2H]2+at m/z = 675.5) and F) neurotensin (no free signal detected, peptide mass = 1674.0). LE and 
galanin are the two neuropeptides in this set where we detect complexes with Aβ1-40 (complexes signals in 
green), while the other neuropeptides screened result in signals for unbound Aβ1-40 (purple) and unbound 
neuropeptide (orange). Poorer signal intensities are recorded in panels C and F due to signal suppression 
surrounding the addition of the neuropeptide indicated.  
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substance P, somatostatin, or neurotensin is not evident in our dataset. The Aβ1-40 binding 
strength is greater for LE than for galanin, as reported in the relative intensity differences 
detected by MS between the free Aβ1-40 monomer peaks and the respective complex ion signals. 
Due to the apparently enhanced strength of the Aβ:LE interaction under the conditions of our 
screen relative to all other neuropeptides studied, we focused on characterizing the structure of 
this complex further.  
Up to 80 µM LE was titrated into a 20 µM Aβ solution, and the resultant complexes were 
detected using IM-MS (Figure 2.2). The 1:1 complex of Aβ1-40:LE is first observed in our IM-
MS data when 10 µM LE is added. At a 1:2 ratio of Aβ1-40: LE, the 1:2 and 1:3 complexes of 
Aβ1-40:LE are detected, both of which occupy a 3+ charge state (Figure 2.2B). Complexes of Aβ1-
40 dimer with LE are also observed with lower intensity in the Aβ1-40:LE mixture (20/60 µM, 
respectively) (vide infra). The Kd value for each of the Aβ1-40:LE complexes identified were 
calculated as an average across the concentration ramp (Table 2.1). Measured Kd values for 
Aβ:LE complexes are in the low µM 
range, with similar Kd values for both 
the monomer and dimer complexes. 
While the 1:1 complex exhibits a Kd 
of 61.7 µM (similar to the Kd we 
measure for the Aβ dimer, at 56 µM), 
the 1:2 and the 1:3 complexes 
possess Kd values of 99.2 and 55.7 
µM respectively, indicating a slight 
thermodynamic barrier in the 
formation of Aβ:2LE. Aβ dimer, 
however, does not exhibit signs of a 
similar barrier, as LE-related Kd 
values are recorded to be 76.7 and 
49.8 µM for the formation of the 2:1 
and the 2:2 complexes, respectively.  
Figure 2.2 – A) MS spectra for Aβ1-40 acquired at 20 µM (purple). 
Aβ1-40 was then incubated with increasing concentrations of LE, 
ranging from 10-80 µM (stoichiometric ratios from 0.5 to 4). At 
sufficiently high LE concentrations, Aβ1-40 is seen in complex with 
LE, producing Aβ:LE complexes ranging from 1:1 to 1:3. B) A 
magnified region of the spectrum shown in A (grey highlight), wher 
signals corresponding to Aβ:LE complexes are labeled.  
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Using IM-MS, it is possible to measure the CCSs of both free Aβ1-40 and Aβ:LE complexes 
simultaneously (Figure 2.3). While the 3+ charge state of Aβ1-40 and the Aβ1-40 monomer: LE 
complexes all occupy a single closely related family of structures, as evidenced by the drift time 
profiles recorded for these ions, the 4+ Aβ1-40 monomer has at least two main conformational 
families, along with a third minor structure for which we did not record data here29. The more 
compact form of Aβ 4+ has a CCS of 622 Å2. These values are similar to previous reports29. The 
measured cross section of LE is 165 Å2; however, the change in CCS of Aβ1-40 monomer when 
in complex with LE is only 44-47 Å2 indicating a closely packed interaction. The changes in size 
for the dimer complexes are similar in magnitude to those of the monomer (27-51 Å2), also likely 
representing a tightly packed complex. The intensities that we observe for the Aβ dimer-based 
complexes are lower than those of the Aβ monomer-related complexes (Figure 2.3D), likely due 
to the lower concentration of free Aβ dimer in solution.  
 
 
Figure 2.3 – A) IM-MS data for Aβ1-40 (20 µM) incubated with LE (60 µM) for 1 h on ice, where 
Aβ:LE  complexes are labeled, along with free peptide. IM separation allows for the identification of 
Aβ dimer complexes previously undetected by MS alone. Aβ1-40 is seen in complex with LE at 
stoichiometric ratios up to 1:3 Aβ1-40: LE and 2:3 Aβ1-40: LE. B) MS dataset for the IM-MS plot 
shown in A. C) Two main conformations of Aβ1-404+ are identified, with a third minor conformer, as 
observed previously29. D) A magnified region of the IM-MS data shown in A, showing detail on 
Aβ1-403+:LE complexes. Monomer complexes are observed in greater relative abundance than those 
related to dimeric Aβ1-40. 
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Table 2.1 – Kd values for LE:Aβ1-40 complexes measured by MS 
Complex Kd (µM) σ 
Aβ1-40 Dimer 56.0 44.7 
[Aβ1-40 + LE] 61.7 27.2 
[Aβ1-40 + LE2] 99.2 30.6 
[Aβ1-40 + LE3] 55.7 21.7 
[Aβ1-40 dimer + LE] 76.7 15.6 
[Aβ1-40 dimer + LE2] 49.8   6.5 
 
To visualize the most likely configurations of the 1:1 Aβ1-40:LE complex, rigid peptide-flexible 
ligand docking followed by simulated annealing MD was performed. Of the 2000 resultant 
structures after annealing simulations, 1090 had CCS values within 3% of the experimentally 
measured value for the complex (638 Å2), as calculated by the trajectory method. These 
structures were additionally filtered by the energy axis from MD data, resulting in 201 sample 
structures that are mostly-likely to represent the structure of the gas-phase ions in our 
experiments. From this population, a lowest-energy sample configuration was compared to both 
the starting NMR (PDB ID: 2LFM) and LE docked structures in Figure 2.4B-D. We further 
analyzed the 201 low energy structures to determine the LE side-chain groups within 4 Å of any 
Aβ1-40 residue and counted these as potential interactions. As expected, models indicate, the 
hydrophobic residues Phe and Tyr in LE interacted more frequently with Aβ1-40 than the Leu and 
in much greater frequency than the two Gly residues. The Aβ1-40 region with most frequent LE 
interactions in our MD dataset lies in the region between residues Glu-3 and Lys-16, with the 
most frequent LE interactions occurring with the Arg-5, Tyr-10, Glu-11, Lys-16, and Glu-22 side 
chains. Generally, our MD results, filtered according to our experimental CCS data, indicate that 
LE interacts preferentially with the N-terminus and hydrophobic core of the Aβ1-40 monomer.  
In order to assess whether the interaction of LE with Aβ1-40 could influence aggregation of the 
peptide, in vitro aggregation studies were conducted and samples of the resulting Aβ species 
were analyzed by gel electrophoresis/ Western blot and TEM. (Figure 2.5).  The gel 
electrophoresis/Western blot results present the distribution of Aβ species, including aggregates 
that are able to penetrate the gel, based on their molecular weight (MW)29, 43-46, 49. Upon 
incubation of Aβ species with LE (1, 3 or 5 equiv.), the amount of Aβ species with MW ≤ 25 
kDA, visualized in the gel, is relatively increased compared to that observed under LE-untreated 
conditions. (Figure 2.5A). For a qualitative comparison against these gel results, TEM was used 
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to identify whether LE could restructure gross Aβ 
aggregate morphology (Figure 2.5B). In the 
absence of LE, large Aβ aggregates with mainly 
fibrillary morphologies are indicated. On the 
other hand, from the samples containing Aβ and 
LE (3 or 5 equiv.), shorter fibrillar species are 
shown as the main Aβ species. Taken together, 
LE demonstrates an ability to moderately alter Aβ 
aggregate formation in vitro.  
2.4. Discussion 
Neuropeptide screening results shown in Figure 
2.1 not only indicate Aβ:LE and Aβ:galanin 
complex formation, but also detect no direct 
complexes between Aβ and substance P, a 
neuropeptide known to possess neurotrophic 
properties with respect to Aβ-induced 
neurotoxicity50. This result suggests that either 
substance P interacts with larger toxic oligomers 
that are not detected in our IM-MS datasets, or 
that the action or substance P is related to its role 
as a neuronal agonist, where it may act to block 
Aβ interactions with critical cell surface 
receptors. The original work identifying the 
neurotrophic effects of tachykinin neuropeptides 
in the context of Aβ localized the critical amino 
acid sequence involved in the putative interaction 
to GSNKGAIIGLM, which shares broad 
sequence homology within the tachykinin family 
and corresponds to residues 25-35 of the Aβ 
peptide21. This sequence bears little resemblance to the amino acid sequence of either LE 
Figure 2.4 – A) Output from all molecular dynamics 
simulations. The lowest energy 201 structures with CCS 
values within ±3% of experimental are highlighted 
(purple box). B) The structure of Aβ monomer (PDB 
2LFM). C) A docked structure of Aβ (PDB 2LFM) with 
LE using AutoDock Vina. D) A representative low 
energy model (indicated in A) from the main structural 
family identified from our MD simulations, in agreement 
with experimental CCS values. Colors represent the N-
terminus (green), core/helix region (blue), and the C-
terminus (orange). E) A plot of the standard score (Z-
score) for Aβ residues within 4Å of the bound LE. 
Larger values denote contacts of greater significance on 
the standard deviation (σ) scale. Negative values denote 
contacts of reduced significance. 
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(YGGFL) or galanin (GWTLNSAGYLLGPHAVGNHRSFSDKNGLTS). For example, the 
strongest identity between galanin and Aβ25-35 exist in a six amino acid sequence between 
residues 23 and 28 in glanin and residues 2 through 7 in the Aβ fragment, resulting in only a 
33% sequence identity within that region. Since early reports for Aβ:tachykinin interactions 
suggested that the C-terminus of Aβ played a role21, the fact that our results for peptides that 
contain little sequence identity to tachykinins and target the N-terminus is not surprising. 
Interestingly, galanin has also been implicated in the etiology of AD, as the peptide has been 
found within fibrils innervating surviving cholinergic neurons51. While known physiological 
concentrations of both neuropeptides is insufficient to drive the formation of the relatively weak 
interactions discovered in this report in vivo, the local concentrations of these peptides, which 
generally co-localize with Aβ52, may be sufficient to interact with Aβ and influence complex 
equilibria towards the complex formation. 
IM-MS structure and oligomer population data for peptides and proteins must be interpreted 
carefully due to the relatively unique environment employed during the analysis. First, during the 
nESI process, many peptides may be trapped in rapidly evaporating droplets and are thus forced 
to generate artificial complexes due to solvent evaporation53. While this situation is typically 
avoided by simply lowering the overall sample concentration26, the concentration accessed in 
this report is in excess of those that typically limit the production of ESI-artifact oligomers. The 
data in Figure 2.1, however, serve as control experiments in this regard, validating the specificity 
of the interactions identified for LE and galanin against a panel of either larger or similarly sized 
peptides. No Aβ complexes were detected for the other peptides in our panel (i.e. substance P, 
somatostatin, or neurotensin), even when added in large excess in solution, indicating that 
oligomers observed in our IM-MS data are both specific to LE and galanin and likely formed in 
solution. Since the structural measurements generated by IM-MS take place in the gas-phase, a 
certain amount of local structural rearrangement is expected for peptide complex ions. Such 
rearrangements can be observed in Figure 2.4D. The key to utilizing gas-phase IM-MS data 
effectively in assessing the structure of biomolecules is to seek evidence of correlated structural 
elements, rather than a wholesale identity between solvent-free and native-state structures54. 
However, we find that the binding region likely accessed by LE in solution is apparently retained 
in our lowest energy gas-phase structures and, indeed, throughout our simulation results (Figure 
2.4E) despite the rearrangements observed for the Aβ peptide backbone. We also note that while 
48 
 
the Aβ data presented here focuses on positive ions, most reports of IM-MS data for this peptide 
contain data for negative ions in order to exploit its charge obtained in solution to simplify data 
interpretation and MD simulations55. While we are actively pursuing negative ion mode data for 
Aβ bound to neuropeptides, the data in this report focused on positive ions primarily to avoid the 
signal intensity and instrumental noise limitations associated with acquiring such data. We 
deemed ion signal intensity of primary importance in our studies due to the relatively weak 
Aβ:neuropeptide interactions we wished to probe. 
Once we overcame the challenges associated with the collection and interpretation of IM-MS 
data on these complexes, we noted several advantages of the method for studying 
Aβ:neuropeptide complexes in comparison to other structural biology tools. The concentration 
range accessed by the IM-MS approach is comparatively low relative to other approaches that 
are capable of recording complex size and shape information56-61. In addition, due to the 
heterogeneous nature of the Aβ:LE complexes interrogated, most spectroscopic probes would 
report structure and Kd values averaged over many co-existing complexes and assemblies. We 
found IM analysis to be especially important in the detection of dimer-related complexes, which 
may have gone completely overlooked if detected by MS alone. The plots shown in Figure 2.3 
group these signals together to form a trend line easily distinguished from other signals 
associated with Aβ and LE62. Trends observed for the CCS associated with the addition of LE to 
Aβ are especially informative (Table 2.2) and indicate that highly compact forms are favored for 
this complex in the context of both Aβ monomers and dimers. Interestingly, the compactness of 
the resulting complex recorded by IM-MS has no correlation with the resultant binding constant 
of that complex (Kd, Table 2.1), perhaps providing additional evidence of local structural 
rearrangements in these Aβ:LE assemblies upon introduction to the gas phase. Finally, the ability 
to evaluate individually the structure and stability of Aβ:LE complexes is a feat that few other 
techniques can accomplish, and as such the values reported here, while in broad agreement with 
other studies of Aβ stability29 form a unique resource on Aβ:neuropeptide interactions. 
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Table 2.2 – CCS values for LE:Aβ1-40 complexes measured by IM-MS 
Complex m/z CCS (Å2) σa 
LE+ 557.0 165   0.22 
Aβ1-404+ 1083.5 622 13.2 
Aβ1-404+ 1083.5 678   0.29 
Aβ1-403+ 1444.3 594   0.38 
[Aβ1-40 + LE]3+ 1629.6 638   0.84 
[Aβ1-40 + LE2]3+ 1815.0 683   0.43 
[Aβ1-40 + LE3]3+ 2000.3 731   0.18 
Aβ1-40 Dimer5+ 1733.0 946 12.7 
[Aβ1-40 dimer + LE]5+ 1844.2 982   0.21 
[Aβ1-40 dimer + LE2]5+ 1955.4 1032   1.54 
[Aβ1-40 dimer + LE3]5+ 2066.6 1060 22.6 
 
a Standard deviation from measurements in triplicate. For real errors, including those from IM calibration, an 
additional ~3% must be added to these values. 
 
The ability of endogenous or exogenous molecules to modulate Aβ aggregate formation has been 
of interest, primarily in an effort to redirect aggregation from producing toxic intermediates. 
Altering the thermodynamics and/or kinetic parameters of this process using molecules like LE 
could offer insight into this problem; however, traditional methods to access the degree of fibril 
formation, such as the fluorescence-based assay using the amyloid-specific dye thioflavin-T 
(ThT), do not always adequately represent these changes29, 42, 63, 64. In the case of LE, its inherent 
interactions with both ThT and Aβ aggregates would have interfered with data interpretation 
(data not shown). Thus gel electrophoresis/Western blot studies in conjunction with TEM could 
offer a more complete picture of the ability of LE to influence Aβ1-40 aggregation. Upon 
incubation of Aβ with LE, there are slightly different distributions of peptide sizes detected by 
gel electrophoresis/Western blot studies, compared to that from the LE-untreated Aβ sample, 
indicating that LE could not completely block or alter the fibril formation trajectory. To 
complement these results, TEM images show differences in aggregate morphology that occur 
during aggregation when LE is present, particularly on larger aggregates. While the aggregate 
populations could not be completely characterized or quantified by TEM, primarily larger sized 
aggregates can be visualized. The TEM images display that samples containing excess LE (e.i. 3 
or 5 equiv.) indicate altered aggregates of large sizes (e.g., mainly shorter fibrils), which is 
consistent with the gel data that showed minimal changes to low MW populations. Thus, weak 
ligand binding may not preclude it from influencing downstream fibrillization provided that 
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interactions occur near the N-terminus of Aβ, similar to LE; however, adjustment of additional 
parameters in such compounds might be required to fully alter structural properties of Aβ 
aggregates at earlier stages. 
The Aβ:LE binding region identified in Figure 2.4 possesses some features similar to the Aβ 
binding region previously identified in our work with (-)-epigallocatechin-3-gallage (EGCG), a 
natural product found in green tea29. Many previous reports have identified EGCG as a potent 
inhibitor of Aβ fibril formation and toxicity65, 66. Our very recent work has further indicated that 
the main role of EGCG in inhibiting Aβ fibril formation likely relies on critical interactions with 
bound metal ions, such as Cu(II) and Zn(II)29. Like LE, we found that the EGCG binds 
preferentially to the cleft between the N-terminus and central helix regions of metal-free Aβ1-4029. 
EGCG and LE bind to this region of Aβ1-40 with similar affinities (Kd relative to Aβ monomer for 
both LE and EGCG are both in the µM range) in the absence of metal ions; thus, both produce 
relatively similar downstream effects in Aβ fibril formation once bound (Figure 2.5). EGCG has 
been found to improve cell viability and recover neuronal activity when Aβ is present, thus 
making the natural product a key target in AD drug design efforts29, 65. While the data presented 
in this report is too preliminary to make similar claims related to the potential of LE as a general 
scaffold or optimization target for future AD therapies, it is clear from the data presented here 
Figure 2.5 – Influence of LE on Aβ1-40 aggregation in vitro. A) Visualization of Aβ species generated in the absence 
and presence of LE by gel electrophoresiss and Western blotting (6E10). Experimental conditions: [Aβ1-40] = 25 
µM; [LE] = 0, 25, 75, or 125 µM; 100 mM ammonium acetate, pH 6.9; 37 °C; 24 h; agitation. B) TEM images of 
Aβ species in the absence and presence of LE (3 and 5 equiv.) from samples in A. The scale bar depicts 500 nm. 
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that the nature of the binder, as well as the binding site accessed, both play significant roles in 
tuning the ability of small molecules to modulate Aβ fibril formation and ameliorate disease 
phenotypes. 
2.5. Conclusions 
Here, we describe studies employing IM-MS, MD simulations, gel electrophoresis/Western blot, 
and TEM which determine both the presence and structure of Aβ:LE complexes, as well as their 
influence on Aβ oligomerization and fibril formation. In addition to LE, our IM-MS data on a 
limited panel of neuropeptides detected Aβ:galanin interactions, but no complexes were detected 
between Aβ and somatostatin, neurotensin, or substance P. The latter result is especially 
informative, as it indicates that previously identified neurotrophic effects for substance P relative 
to Aβ are likely the result of the neuropeptide interacting with larger Aβ oligomers or due to its 
agonist activity relative to neuronal receptor sites. Aβ:LE complexes ranging in stoichiometry 
from 1:1 to 2:3 are detected ion our dataset, and CCS values indicate that the complexes favor a 
compact configuration. A detailed IM-MS analysis of Aβ:LE complexes indicates that the small 
neuropeptide is likely bound in a cleft between the Aβ N-terminus and its hydrophobic core 
region in a manner similar to EGCG29. The gel/Western blot data suggest minimal change in the 
size distribution of the Aβ species incubated with LE, but TEM data for Aβ samples doped with 
LE display mainly shorter fibrils in lieu of potentially non-toxic amorphous aggregates that were 
observed in previous work using metal-containing Aβ samples doped with EGCG29. Overall, the 
dataset presented here generates intriguing correlations between binding affinity, binding site, 
and resultant fibril morphology that will likely aid in the pursuit of both small molecules and 
biotherapeutics for AD. Future work in our group will continue to pursue neuropeptides, 
including the interaction with galanin we observed in these data, as potential Aβ binders, fibril 
formation inhibitors, and neurotrophic agents. 
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Chapter 3.  
Ion Mobility-Mass Spectrometry Reveals a Dipeptide That Acts as a 
Molecular Chaperone for Amyloid β 
Previously, we discovered and structurally-characterized an Amyloid β1-40 (Aβ1-40): leucine 
enkephalin (LE, YGGFL) complex.  This work identified LE as a potentially-useful starting 
point for the discovery of peptide-related biotherapeutics for Alzheimer’s Disease (AD). In order 
to better understand LE:Aβ complexes that are formed in vitro,  we describe here the analysis of  
a series of site directed amino acid substitution variant versions of LE and Aβ, covering the LE 
sequence in its entirety, as well as a large number of selected residues of Aβ1-40 (residues: D1, 
E3, F4, R5, H6, Y10, E11, H13, H14, Q15, K16, E22, K28, and V40).  Ion mobility- mass 
spectrometry (IM-MS) and molecular dynamics (MD) simulations reveal that the hydrophobic 
C-terminus of LE (residues FL) is crucial for the formation of Aβ:LE. As such we explore here 
the interaction of the dipeptide phenylalanine-leucine (FL) with wild both type (WT) and variant 
forms of Aβ using IM-MS, MD, Transmission Electron Microscopy (TEM) and circular 
dichroism (CD) spectroscopy in order to structurally characterize Aβ:FL. We find that FL binds 
within the region between the N-terminus and the hydrophobic core, most specifically at residue 
Y10 and Q15. We further show that FL is able to prevent Aβ fibril formation, thus providing 
another step toward the discovery of a potent AD therapeutic.  
3.1 Introduction 
The utility of IM-MS as a tool for drug development, especially in the context of protein 
misfolding diseases such as Alzheimer’s Disease (AD) and Type II Diabetes, has recently 
emerged1-10. While many hypotheses surrounding the causation of AD are proposed, a prominent 
theory is that the uncontrolled aggregation of Aβ peptides, which form small toxic oligomers 
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(dimer to dodecamer) leads ultimately to neuronal cell death11-15. As Aβ aggregation allows for 
many oligomeric states simultaneously, studying Aβ oligomers for the purposes of drug 
discovery is difficult with classical biophysics and structural biology techniques16. IM-MS 
allows for the use of low concentrations, small sample volumes, and separates protein oligomers 
based on mass and collision cross section (CCS)17-19 making it an ideal technology for the 
analysis of Aβ-small molecule complexes . 
We previously reported on a set of experiments that identified Aβ-Neuropeptide complexes , and 
having the ultimate goal of identifying a peptide, or peptide fragment, which might inhibit Aβ 
fibril formation and provide a scaffold for future potential biotherapeutics20. In these data, we 
found evidence of interactions between Aβ1-40 and both leucine enkephalin (LE) and galanin.  
We characterized the former in detail, providing CCSs, binding affinities (Kd), and molecular 
dynamics (MD) simulations.  In addition, we studied the ability of LE to inhibit Aβ fibril 
formation using both TEM and gel electrophoresis. Complexes containing Aβ and LE were 
detected in stoichiometric ratios ranging from 1:1 to 1:3, and from 2:1 to 2:3 Aβ:LE. At 
increased concentrations of LE, our data indicated that attachment to Aβ dimers is favored over 
binding to the monomeric form. Kd values were measured in the µM range for these complexes, 
and molecular dynamics (MD) led the determination of the likely binding location of LE, along 
the N-terminus of the Aβ sequence, similar to other natural products5. TEM and gel data reported 
a truncation of Aβ fibrils and an increased amount of lower molecular weight Aβ oligomers 
when incubated in excess with LE, compared with control. 
Here we report on IM-MS measurements of complexes formed between Aβ and the site directed 
amino acid substitutions of the entire sequence of LE, which indicate that the hydrophobic C-
terminal residues (phenylalanine and leucine) are critical for the formation of Aβ:LE 
interactions. Furthermore, we study the dipeptide phenylalanine-leucine (FL) and its complexes 
formed with Aβ sequence variants. For 1:1 Aβ:FL complexes, we identify residues Y10 and Q15 
as possessing key interactions with FL, necessary for strong complex formation. This 
observation matches well with the predicted location of FL binding from MD simulations of 
Aβ:LE20. MD simulations of Aβ:FL were conducted and models filtered using IM-MS  data. 
From these, we predict FL interacts with Aβ primarily through Y10, and that these interactions 
occur mostly through a series of specific interactions with the C-terminal residue of FL.  
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Importantly, FL interacts more strongly with Aβ dimers, and Aβ:FL complexes containing the 
more pathogenic Aβ1-42, appear to bind in a similar mode to that of Aβ1-40:FL. Finally, we use 
TEM analysis to study Aβ fibril formation in the presence of FL, finding strong evidence of the 
inhibition of fibrilization.  We conclude by discussing the potential impact of FL as a scaffold for 
the future development of AD therapies.     
3.2 Experimental  
3.2.1 General 
Reagents were purchased from commercial sources and used without further purification unless 
otherwise specified. Aβ1-40 was purchased from Anaspec (Fremont, CA, USA). Alanine 
mutations were custom synthesized and received at a purity of at least 95% (GenScript, ). Aβ 
variants (1 mg) were dissolved in 200 µL 1% (v/v) ammonium hydroxide and diluted with pH 
6.9 100 mM ammonium acetate (Sigma-Aldrich, St. Louis, MO, USA) to a total volume of 1500 
µL. Peptides were then injected into a Slide-A-Lyzer Dialysis Cassette (2K MWCO, 3 mL 
volume, Thermo Scientific). 100mM ammonium acetate was added to fill volume of cassette 
capacity, and dialysis was performed over a 24 h period. Samples were then removed from the 
cassette, flash frozen with liquid nitrogen and lyophilized overnight. Peptides were reconstituted 
using 200 µL 1% (v/v) ammonium hydroxide and diluted with pH 6.9 100 mM ammonium 
acetate to a total volume of 1500 µL. Peptide concentration for the stock solution was calculated 
from absorbance at 280nm (ε = 1490 M-1 cm-1). Peptides were aliquoted and stored at -80 °C. LE 
acetate hydrate (YGGFL) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and 
prepared in pH 6.9 100mM ammonium acetate. FL was synthesized by AnaSpec, and prepared in 
dimethylsulfoxide (Sigma-Aldrich, St. Louis, MO).  
3.2.2. IM-MS 
Mass spectra were collected on a quadrupole-ion mobility-time-of-flight (TOF) mass 
spectrometer (Synapt G1 HDMS, Waters, Milford, MA, USA) with a nano-electrospray 
ionization (nESI) source. Protein ions were generated using a nESI source and optimized to 
allow transmission of noncovalent protein complexes using electrospray capillaries prepared as 
described previously21. Protein complex ions were generated using an aliquot of the sample (ca. 
7 µL) sprayed from the nESI emitter at a capillary voltage of 1.2kV. The source was operated in 
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positive ion mode with the sample cone at 35 V and extraction cone at 1.0V. The bias voltage 
was 21 V, with backing pressure at 2.32 mbar and TOF pressure at 1.81 x 10-6 mbar. The 
travelling-wave IM separator was operated at a pressure of approximately 3.0 mbar of nitrogen. 
Mass spectra were calibrated externally using a solution of cesium iodide (100 mg mL-1) and 
analyzed using MassLynx 4.1 and Driftscope 2.0 software (Waters, Milford, MA, USA). CCS 
(Ω) measurements were externally calibrated using a database of known values in helium, using 
values for peptides and proteins that bracket the likely CCS and ion mobility values of the 
unknown ions22, 23. Samples were prepared by mixing stock solutions (as prepared above) of 
neuropeptide and Aβ1-40 variants at pH 6.9, to generate a final Aβ1-40 concentration of 20 µM, 
with 2.88% v/v DMSO present in all samples. Samples were incubated on ice for 1 h prior to IM-
MS analysis.  
3.2.3. Docking Studies 
Flexible ligand docking studies were preformed using AutoDock Vina24. FL was created using 
PyMOL and studies were conducted against the Aβ1-40 monomer (aqueous solution NMR 
structure PDB 2LFM)25 and Aβ1-42 (aqueous solution NMR structure PDB 1Z0Q)26. Twenty 
docking studies with Aβ1-40 and thirty docking studies with Aβ1-42, one with each conformation 
within the PDB files, were performed. The structures for FL and Aβ were prepared for use with 
AutoDock vina using AutoDock Tools24. All hydrogens were added to Aβ and torsions were kept 
as the default selected in AutoDock Tools. The exhaustiveness for the docking studies was set at 
8, resulting in 9 output models for each Aβ conformation. Docked models of FL were visualized 
with Aβ using PyMOL. 
3.2.4. MD Simulations 
Simulations were started using the minimized Aβ solution NMR structures (PDB 2LFM or PDB 
1Z0Q)25, 26. Charges were applied to R5, K16, and K28 to mimic the 3+ charge state observed in 
the gas phase. The simulations were performed using periodic boundary conditions in a 
dodecahedron with the minimum distance between the simulated molecules and the box wall 
being 1.0 nm. GROMACS ligand topology was prepared using the GlycoBioChem PRODRG2 
server27. The MD simulations were carried out using the GROMACS software package28 and 
GROMOS96 force field29. To constrain the bond length in the Aβ and FL, the LINCS algorithm 
was used, allowing an integration time step of 2 fs. Long-range electrostatic interactions were 
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treated with the particle mesh Ewald method. Temperature was maintained using the method of 
Berendsen et al30. The FL and the Aβ were separately coupled to external temperature bath with 
a temperature-coupling constant of 0.1 ps.  
The system was energy-minimized by steepest decent for 500 steps. After equilibration, 
simulated annealing was performed for the Aβ: FL complex in the gas-phase. The three most 
basic Aβ side chains (R5, K16, and K28) were charged. The system was heated from 300 K to 
500 K over 100 ps, then cooled down to 300 K over the next 100 ps. The cycle was repeated over 
20 ns in order to allow for escape from local minima and enhance equilibration. For the Aβ1-40: 
FL complex, 20 independent simulated annealing runs, each running for a total of 20 ns, were 
performed from the lowest energy complexes generated by AutoDock Vina. For the Aβ1-42: FL 
complex, 30 independent simulated annealing runs, each running for a total of 20 ns, were 
performed from the lowest energy complexes generated by AutoDock Vina. From the MD 
trajectory generated, 100 structures were sampled at 300 K and the CCS was calculated with 
Mobcal using the trajectory method algorithm31, 32. Models of the Aβ:FL complexes were 
visualized in PyMOL. In total 2000 structures were generated for Aβ1-40 and 3000 structures for 
Aβ1-42. Of the structures which were within ± 3% of the experimentally determined CCS, the 200 
structures with lowest energy were analyzed to determine the Aβ residues within 4 Å of FL. 
Standardized values (Z-scores) were calculated for each residue of Aβ1-40 and Aβ1-42 and plotted 
in standard deviation (σ) space in order to determine the relative likelihood of FL binding within 
a given region of Aβ.    
3.2.5. Hierarchical Clustering Analysis 
Structures of Aβ1-40:FL, following MD simulations, which were within ± 3% of the experimental 
CCS, and which matched site directed amino acid substitution experiments (FL was within 4 Å 
of Aβ residue Y10 and Q15). This reduced the set of possible structures from 963 to 60. We then 
characterized the structural families present in the dataset using hierarchical clustering. Aβ 
candidate structures were temporarily stripped of their ligands while being aligned using the 
Kabsch algorithm33, and pairwise RMSD values were calculated for each structure in the dataset. 
These pairwise RMSD values were then used as a distance matrix for hierarchical clustering 
using the average linkage clustering module from Scipy34. Intra and inter-cluster RMSD values 
were analyzed and it was found that the dataset could reasonably be broken into 5 clusters, 
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allowing for facile interpretation of the dataset. For each structural cluster, and average structure 
was calculated to represent the structural family, and all ligands were then superimposed on the 
representative structure, revealing strong structure-specific ligand clustering, in addition to an 
averaged ligand location. Structures were visualized in PyMOL. 
3.2.6 Kd Measurements by MS  
Dissociation constant (Kd) values for the neuropeptides with Aβ1-40 were calculated using the 
relative intensity of each species from the mass spectra, as described previously35. Previously20, 
we modified this method to accommodate multiple ligand binding events with the following 
assumptions: (1) the spray and detection efficiency of all species are similar, (2) the ligand 
concentration is sufficiently high so that [L]eq remains constant and (3) the ligand binds to the 
complex one at a time in a stepwise fashion. Here we present further modification to better 
represent multiple ligand binding stoichiometry.  
For the equilibrium binding of A (unbound protein) and B (a ligand/binding partner): 
𝐴𝐴 + 𝐵𝐵 ↔  𝐶𝐶1 +  𝐶𝐶2 + ⋯+  𝐶𝐶𝑥𝑥   (3.1) 
𝑅𝑅𝑥𝑥 =  [𝐶𝐶𝑥𝑥]𝑒𝑒𝑒𝑒[𝐴𝐴]𝑒𝑒𝑒𝑒      (3.2) 
Where Rx is an equilibrium quotient between the bound form of the protein (Cx, having x ligands 
attached) when interacting with ligand B, and is unbound for (A). 
[𝐶𝐶𝑥𝑥]𝑒𝑒𝑒𝑒 =  𝑅𝑅𝑥𝑥([𝐴𝐴]0−(∑ 𝑦𝑦[𝐶𝐶𝑖𝑖]𝑒𝑒𝑒𝑒))𝑥𝑥−1𝑖𝑖=11+𝑦𝑦𝑅𝑅𝑥𝑥     (3.3) 
Eqn (3.3) above defines Rx for all bound forms of the protein (Ci), where y is the number of 
species A in the complex and: 
   𝐾𝐾𝑑𝑑𝑥𝑥 =  [𝐶𝐶(𝑥𝑥−1)]𝑒𝑒𝑒𝑒[𝐵𝐵]𝑒𝑒𝑒𝑒[𝐶𝐶𝑥𝑥]𝑒𝑒𝑒𝑒      (3.4) 
Allows for the determination of Kd for any given step in the sequential equilibrium described in 
eqn (3.1), where C0 = A. Standard deviation values (σ) for the Kd measurements reported here 
are shown from three replicate measurements. 
3.2.7 TEM  
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Negatively stained specimens for transmission electron microscopy were prepared by applying 5 
µL of peptide solution to hydrophilic 400 mesh carbon-coated formvar support films mounted on 
copper grids (Ted Pella, Inc.). The samples were allowed to adhere for 3 min, rinsed twice with 
distilled water, and stained for 60-90 s with 1% uranyl acetate (Ted Pella, Inc.). All samples were 
imaged at an accelerating voltage of 60 kV in a CM-100 electron microscope (Philips, Inc.). 
Samples were prepared in 100 mM ammonium acetate, with 2.88% DMSO at a concentration of 
25 µM Aβ and allowed to incubate at room temperature for 24 h.  
3.3 Results and Discussion 
As a follow up to our previous work investigating the detailed structures of LE:Aβ complexes,20 
we undertook a series of IM-MS experiments using a comprehensive set of site-directed amino 
acid substituted forms of LE (YGGFL). Each of these five LE variants was first evaluated using 
MS intensity values under controlled conditions as a quantitative measure of Aβ1-40 complex 
formation. (Figure 3.1A). Substitution of the first three residues in the LE sequence (tyrosine and 
both glycine residues) yield complex ion signals similar to control experiments under our 
experimental conditions. However, when the two hydrophobic C-terminal residues 
(phenylalanine and leucine) were substituted, neither of these variants are observed to generate 
signals associated with complex formation, indicating their importance in Aβ:LE binding overall.  
Using the information provided by Figure 3.1A, we filtered our previous model structures for the 
Aβ:LE complex20, resulting in a refined population of models where Aβ constituents are within 4 
Å of either the phe or leu residues of LE. This newly-refined model population was used to 
calculate standardized probability values for each residue of Aβ1-40 in terms of their phe or leu 
contacts. This analysis highlights several regions of importance, which are shown in  Figures 
3.1B and C, where a standard score greater than 1 indicates an increased significance of the 
contact observed between the indicated Aβ residue and either the phe or leu on LE, respectively. 
Aβ1-40 residues which most frequently interact with phe are Y10, H14, Q15, K16, E22 and D23, 
and those interacting most frequently with leu are R5, Y10, E11, H14, Q16, K16, and K28.  
Those interacting significantly with both residues are Y10, H14, Q15, K16. This analysis agrees 
overall with our previous models of Aβ:LE complexes, from which we concluded that LE 
binding likely occurs in the N-terminal/ hydrophobic core region of Aβ, similar behavior to other 
natural products5, 20. As such R5, Y10, E11, H14, Q15, K16, E22, and K28 alanine substitution 
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variants of Aβ were targeted for downstream experiments. Of the remaining alanine variants, 
D1A and V40A, as terminal ends were assumed to be negative controls. H6A and H13A were 
selected as a control for H14A while E3 serves as a control for E11A and E22A. Each of these to 
ensure if Kd had changed it was due to a specific location of the residue, not just the side chain 
Figure 3.1 – Interactions between Aβ1-40 and LE variants. A) IM-MS analysis of alanine substituted 
variants of LE reveals complexes formed between Aβ1-40 and AGGFL, YAGFL, and YGAFL in a 
manner similar to WT LE. On the other hand, samples containing YGGAL and YGGFL produce no 
measureable complex signals, indicating phe and leu to be critical for the interaction with Aβ. B and C) 
Plots of the standard score (Z-score) for Aβ residues that are within 4Å of the phe and leu in LE. D) 
Sequence of Aβ1-40, where the N-terminus (green) is defined as residues 1-11, the hydrophobic core 
(blue) is residues 12-23, and the C-terminus is residues 24-40. This color-coding for Aβ1-40 applies to 
all figures.    
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composition. The control F4A, has been suspected in interactions with other potential AD 
therapeutics6, and so was tested here.   
As our data strongly indicates that it is primarily the hydrophobic C-terminus of LE that is 
responsible for its binding to Aβ, we moved to focus our experimental efforts on the dipeptide 
phenylalanine-leucine (FL). IM-MS data acquired from solutions continuing 20 µM Aβ1-40 and 
FL ranging from 10 – 80 µM, reveals the formation of Aβ1-40:FL complexes in ratios of 1:1- 1:4, 
2:1- 2:5, 3:1- 3:4, and 4:1 (Figure 3.2A). Companion MD simulations of Aβ1-40: FL complexes 
yields significant interactions between the dipeptide and R5, Y10, K16, D23, S26, N27, and K28 
from the Aβ sequence. This result agrees in part with our analysis of Aβ1-40:LE models discussed 
above, which predicted R5, Y10, K16, D23, and K28 as likely FL binding sites. While Aβ1-40 is 
found in greater quantities in vivo, Aβ1-42 is theorized to be the more pathogenic variant and 
aggregates more rapidly, making it more difficult to study in vitro. IM-MS data shown in Figure 
Figure 3.2 – Interaction between Aβ with the dipeptide FL. A) IM-MS data shows the presence of Aβ1-40 in 
complex with FL as a monomer, dimer, trimer, and tetramer at 20 µM Aβ: 60 µM FL. Multiple copies of FL 
attach to each oligomer under these concentrations, while at lower FL concentrations (10 and 20 µM) only 1:1 
complexes are observed. B and D) Plots of the standard score (Z-score) for Aβ residues within 4Å of the 
bound FL. Larger values denote contacts of greater significance on the standard deviation (σ) scale. Negative 
values denote contacts of reduced significance. C) IM-MS data shows the presence of Aβ1-42 in complex with 
FL as both monomer and dimer, with up to 4 copies of FL binding to each oligomer at 20 µM Aβ: 60 µM FL. 
As with Aβ1-40, with lower concentrations of FL, fewer FL copies are bound.     
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3.2C indicates that Aβ1-42 binds FL, exhibiting Kd and complex stoichiometry values similar to 
that of Aβ1-40. Low energy models generated for Aβ1-42: FL complexes exhibit a strong 
preference toward binding within the hydrophobic core of Aβ1-42, specifically with residues E11, 
V12, H13, Q15, and K16, an observation that is generally retained from our Aβ1-40 MD and 
experimental data as well. 
To more-clearly elucidate the binding location of FL within the Aβ1-40 sequence, Kd values were 
extracted from the MS data acquired for all alanine substituted Aβ variants listed above, in 
addition to control variants: D1A, E3A, F4A, H6A, H13A, and V40A. All control residues 
represent regions of the Aβ sequence that MD IM-MS-filtered models did not highlight as 
critical for LE binding. Of the fourteen alanine variants, only three produced Kd values 
significantly greater than those recorded for the WT Aβ1-40:FL 1:1 complex (Kd = 58.1 ± 25.9 
µM). These variants include Y10A, Q15A, and E22A (Kd = 135 ± 71.3 µM, 126 ± 86.6 µM, 112 
± 53 µM respectively).  Neighboring variants E11A, H14A and K16A do not deviate 
significantly from WT. In fact the mutations R5A, K16A, and K28A all fall within error of the 
WT value, demonstrating the lysine and arginine residues of Aβ have no impact on FL binding. 
Of the control cases, D1A, E3A and H13A behaved similarly to the WT as expected. The 1:1 
complex of F4A:FL was only observed twice in seven samples, one at low concentration of FL 
and one at high, measured Kd, was averaged to 117 µM, but without a standard deviation. Aβ1-40 
F4A which was detected outside of the complex was heavily adducted with non-volatile salts, 
calling to question their effect on the binding events. In contrast to those which were within error 
of the WT, two variants, H6A and V40A, produced significantly reduced Kd values relative to 
WT, 27.5 ± 14.8 µM and 17.2 ± 8.5 µM respectively.  Taken together, these data indicate that 
residues Y10, Q15, and E22 likely provide key molecular contacts that stabilize the Aβ1-40:FL 
complex, while H6 and V40 provide a destabilizing or screening effect that, when removed, 
improves the strength of the resulting complex significantly. In order to validate the structures of 
the variant forms of Aβ1-40 are not significantly altered from that of the WT sequence, CD 
spectroscopy data was acquired for all alanine variants and WT Aβ peptides (data shown in 
appendix II). While Y10A and Q15A peptides have CD signatures similar to that of Aβ1-40, the 
CD spectrum acquired for E22A exhibits a pronounced β-sheet structure similar to that of Aβ1-42. 
The known familial mutation E22G (Arctic mutation) of Aβ1-40 has shown an increased 
propensity for aggregation and behavior mimicking Aβ1-4236. The alanine variant E22A differs 
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from this mutation by only a methyl group and was suspected to mimic E22G structurally, 
making the CD results unsurprising. As such, CD data supports an analysis of our IM-MS Kd 
data interpreted on the basis of only the altered molecular contacts within the FL:Aβ binding 
surface for Y10A and Q15A, but strongly suggests that E22A Kd data is a product of both altered 
Figure 3.3 – Site directed amino acid substitution effects on FL 
biding. A) Shown is a representative spectra of 20 µM Aβ1-40 variant 
incubated with 80 µM FL for 1 h on ice. The grey boxed region 
indicates the 1:1 complex detected at a 3+ charge state. Signal for the 
1:1 complexes of Y10A: FL and Q15A: FL show decreases in 
intensity when compared to the WT interaction. B) Kd values 
calculated for each amino acid substitution. Error bars indicate 1 
standard deviation (σ). WT interaction is shown in red. The yellow 
bar is ±1(σ) of the 1:1 complex. The 1:1 interactions are shown as the 
darkest shade, 1:2 in medium shade, and 1:3 as the lightest. Of the 
1:1 interactions only Y10A, Q15A, and E22A are above 1 σ different 
than the WT. All 1:2 interactions fell within standard deviation of the 
WT 1:2 interaction and a WT 1:3 interaction could not be measured 
in triplicate 
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peptide conformation and available FL interactors within the Aβ sequence. Multiple FL binding 
events to Aβ (1:2 and 1:3 Aβ:FL) yielded weaker Kd values than that of the 1:1 interaction for all 
variants where 1:2 or 1:3 complexes were detected. Additionally all measurements of the 1:2 
complex were within error of each other,  indicating no strong preferences in higher-order FL 
binding among those tested here. Kd values for alanine variants with LE, as well as values 
acquired for higher order Aβ:LE complexes, are available with discussion in appendix II.  
To evaluate the ability of FL to alter Aβ fibril formation, TEM images were acquired for Aβ1-40 
samples containing FL.  For example, the features observed in 
the TEM data shown in Figure 3.4 have a marked dependence 
upon FL concentration, with long mature fibril structures 
observed for Aβ samples where no FL is added, to truncated 
fibril structures in samples where equimolar FL is added, and a 
complete abrogation of Aβ fibril formation when excess FL is 
present. Truncated fibrils observed by TEM upon equimolar 
FL addition to Aβ samples are less dense when compared to 
control samples, further indicating that mature fibril formation 
is weakly inhibited under these conditions. The weakly-stained 
forms observed under conditions of FL excess appear 
universally amorphous, indicating that while Aβ aggregation 
still occurs, it likely does so through an altered route that may 
not produce toxic species, which have been observed in 
previous studies37.   
Using all the data described above, we filtered the output of 
MD simulations to produce a range of models that describe the 
molecular details of the Aβ1-40:FL complexes observed in our 
experiments. Our workflow begins by filtering all models that 
have CCS values outside of our experimental error (652.6 ± 
22.1 Å2 for the Aβ1-40:FL complex). Next, we remove all 
models that lack clear interactions (contact within 4 Å) 
between FL and Y10 and Q15, which our experimental data 
Figure 3.4 – TEM images of Aβ1-40 
incubated with equimolar or excess FL 
(as labeled), displaying reduced fibril 
formation upon FL addition.  
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suggest are key elements for the efficient formation of a stable Aβ1-40:FL complex. Hierarchical 
clustering of this filtered model pool yields five structural families. Figure 3.5A shows the output 
of our clustering algorithm, along with low-resolution averaged peptide structures that depict an 
averaged location for FL binding on the Aβ 
surface. In most, FL is cradled between the N-
terminus and the hydrophobic core while the c-
terminus is further away. In two of the families 
however, the FL appears to be closer to C-terminal 
residues. In families where FL is closer to the C-
terminal, the structural average appears to be more 
compact. A detailed, manual analysis of these five 
structural families reveals common themes in the 
molecular contacts created between FL and the 
Q15 residue within the Aβ sequence.  Three 
examples of these details are shown in Figure 3.6, 
where we highlight bonding of FL and Aβ residue 
Q15. A bond distance of 2.8 Å between one 
oxygen of leucine and NE2 of Q15 is observed in 
the lowest energy structure matching our 
experimental restraints (Figure 3.6A). The ligand 
boding is stabilized by R5, H6, and D7 with 
hydrogen bonding distances of 3.1 Å and 3.2 Å 
between R5 and D7 with the oxygen of F, and a 
3.8 Å bond between the nitrogen of F and H6. In 
this particular model, Y10 is too far away from 
the oxygen on L to hydrogen bond. In another low 
energy structure, FL is wrapped tightly within the 
Aβ structure (Figure 3.6B). Here hydrogen 
bonding occurs between NE2 of Q15 and the 
oxygen on F (2.7 Å). While there are no contacts 
Figure 3.5 – Hierarchical clustering analysis and 
model visualization of Aβ1-40:FL complexes. A) 
Clustering hierarchy, and the averaged family 
structure for each cluster. B) High resolution 
representative of Aβ:FL complex. Where Q15 and 
Y10 (teal) primarily interact with the leucine of 
FL. N-terminus (green), hydrophobic core (blue), 
C-terminus (orange), and FL (grey, oxygen in red, 
nitrogen in blue).  
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less than 4 Å between FL and Y10 in this 
model, the ring structure surrounds the FL 
pocket. The interaction is stabilized with a 3.1 
Å bond between the carboxylic acid oxygen 
on V12 and the backbone nitrogen on F, in 
addition to 3 hydrogen bonds between D7 and 
L. Despite the Y10 not being close enough for 
hydrogen bonding in the two models 
discussed thus far, another low energy 
structure from a different cluster does 
demonstrate bonding (Figure 3.6C). Here, 
Y10 has a hydrogen bond distance of 3.0 Å 
with the backbone nitrogen of F, and Q15 
bonds with a distance of 3.0 Å between the 
oxygen on Q15 and the alpha carbon of L. 
The interaction is further stabilized with 
hydrogen bonding between an oxygen of L 
and N of L17 (2.8 Å) and ND1 of H14 and 
the oxygen of F (3.1 Å). Models which do not 
show binding to Y10 pass through our initial 
filter because hydrogen atoms are within 4 Å, 
however, hydrogen bond distances refer to 
heavy atom to heavy atom distances only. We 
note that all FL hydrogen bonding captured 
within our models occur along the backbone. 
As the hydrogen bonds are weak interactions, 
we believe data here only captures a subset of 
all potential interactions. Side-chain specific 
interactions are thus suggested to be possible, 
but undocumented in the three lowest energy 
models detailed here.     
Figure 3.6 – Detailed interaction of Aβ:FL from the 
lowest energy structure of three clusters. Hydrogen 
bonding occurs most frequently with the backbone of 
FL. Bond distances with Q15 range from 2.7-3.0 Å. A 
and B) models in which Y10 has a hydrogen within 4 
Å, but no heavy bonding atoms. C) Model in which 
Y10 and Q15 both hydrogen bond with FL. Y10 and 
Q 15 are shown in teal, FL in white with nitrogen in 
blue and oxygen in red.  
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3.4 Conclusion 
Through a comprehensive set of IM-MS and MD simulation results for a comprehensive series 
of amino acid LE variants, we have identified the two C-terminal residues within the 
pentapeptide as critical for its previously-reported interaction with Aβ. A subsequent IM-MS 
analysis of Aβ complexes formed with the isolated FL dipeptide from LE revealed both 
equivalent binding strengths to the full length construct, and improved attachment to higher-
order Aβ oligomers.  Through detailed IM-MS, TEM, and CD spectroscopy covering 14 alanine 
variants of Aβ1-40, carefully selected through an analysis of MD simulation output, we have 
narrowed the potential sites of FL contact on the Aβ1-40 surface to the Y10 and Q15 residues. 
Molecular models extensively filtered through a range of structural biology data indicate that FL 
primarily interacts with Q15 through hydrogen bonding to the FL backbone, and that the 
dipeptide is cradled between the N-terminus and the hydrophobic core in a manner similar to 
previous Aβ binders of therapeutic note. Critically, TEM data shows that FL inhibits Aβ1-40 fibril 
formation, which further points to its potential as a foundation for future AD therapeutics.  To 
move forward, we look towards chemical modification of the FL dipeptide in the creation of a 
therapeutic library for screening purposes. Modifications should reduce cellular toxicity and 
increase binding affinity. Additionally, NH2-FL and FL-Ac variants are of interest, as it has been 
shown Aβ42 C-terminal fragment NH2-VVIA decreases the toxicity of oligomers38. Further, a 
screen for interaction with other dipeptides may discover complexes with greater binding affinity 
and provide a stronger starting scaffold to build therapeutics from.   
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Chapter 4.  
Ion Mobility Mass Spectrometry Analysis of Ubiquitin and 
Ubiquilin2 Aggregates 
4.1. Introduction 
It is well understood that ubiquitin is crucial to protein degradation1, 2. Three key enzymes 
responsible for this process are E-activating, E-conjugating, and E-ligases3, 4. Where the E-
activating enzyme links its active site cysteine to the c-terminus of ubiquitin. The ubiquitin 
conjugating enzyme forms catalytically activated intermediates. These may form polyubiquitin 
chains with E-ligases5, 6. The ligases can then form isopeptide bonds between the c-terminus of 
ubiquitin and lysine (K48 of ubiquitin) on an already ubiquitin tagged target protein, or lysine on 
the target protein6. This polyubiquitin chain signals the 26S proteasome for degredation7. A 
growing body of work suggests transition metals to be associated with the regulation of this 
process8. Dysfunction of the pathway can also be correlated with neurodegerateive diseases, 
which are further correlated with metal dyshomeostasis 9, 10. In this chapter, IM-MS is used to 
characterize the structural effects of copper binding on ubiquitin aggregation in vitro in attempts 
to better understand its possible interaction in protein degradation and neurodegenerative 
diseases. We find, under conditions of three fold excess copper per ubiquitin subunit, that 
aggregation of ubiquitin increases, and have observed compaction of the ubiquitin monomer 
upon copper binding.           
It is evident that neurodegenerative diseases having etiologies that rely upon protein aggregation 
are, by definition, complex and multifaceted disorders. In addition to the discussion above, the 
ubiquitin-like protein family (UBQLN1-4), is associated with both Alzheimer’s and Parkinson’s 
diseases11. Additionally, dominant X-linked juvenile and adult-onset familial amyotrophic lateral 
sclerosis (ALS) is thought to be caused by mutations in UBQLN212, 13. The UBQLN2 protein is 
comprised of an ubiquitin-like domain, heat-shock-chaperonin-binding motifs, PXX repeats, and 
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an ubiquitin-associated domain. Mutations of UBQLN2 linked with ALS include P497H, P497S, 
P506T, P509S and P525S and are found in the PXX repeat region. All UBQLN family proteins 
have an ubiquitin-like domain and an ubiquitin-associated domain on the termini but the middle 
region is variable. This structural motif allows these proteins  to be involved with directing the 
proteosomal degradation process14. Cells expressing proline mutations of UBQLN2 
demonstrated impaired function of the ubiquitin-protesome degradation pathway, indicating ALS 
and ALS/dementia are associated with altered protein clearance and homeostasis12. P506T 
UBQLN2 inclusions were found in the spinal cord and hippocampus of ALS patients displaying 
dementia12. Little is known of these inclusions bodies, and the direct rolls of potential UBQLN2 
aggregates in human disease 12, 13, 15, 16. In addition to the studies discussed above, we endeavor 
here to determine structural differences between UBQLN2 wild type and the P506T mutant, and 
detect differences in protein aggregation using IM-MS and collision induced unfolding (CIU)17, 
18. We find that both WT and P506T Ubiquilin2 have similar propensity for dimerization and 
nearly indistinguishable unfolding pathways.   
4.2. Experimental Methods 
4.2.1. Ubiquitin Preparation 
Ubiquitin (from bovine erythrocytes, Sigma-Aldrich) and Recombinant Human Linear Tetra-
Ubiquitin/Ub4, CF (R&D systems) were dissolved in 200mM ammonium acetate (BioUltra for 
molecular biology, Sigma) to 50-100 µM, aliquoted as necessary and stocks stored at -80 °C. 
Tri-ubiquitin (linear, Enzo Life Sciences) was left as received in 50 mM TRIS pH 8.0 containing 
50 mM sodium chloride. Prior to IM-MS experiments all ubiquitin samples were buffer 
exchanged using 6kDA MWCO buffer exchange columns (bio-rad) for desalting of ubiquitin and 
tetra-ubiquitin, and for buffer exchange of tri-ubiquitin into 200 mM ammonium acetate. 
Proteins (10-15 µM) were incubated on ice for 3 h in 75/25 v/v 200 mM ammonium acetate/200 
mM triethyl ammonium acetate buffer (TEAA, Sigma) unless otherwise specified. Copper (II) 
acetate was added at concentrations specified.  
Linear Tri-Ubiquitin (L3UB, 10 µM) was incubated with 30 µM CuAc. While this represents a 
3x excess of copper to the L3UB complex, with 100% binding efficiency each of the ubiquitin 
subunits could be copper bound, leaving no excess. To match the 3 fold excess for each subunit 
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represented for monoubiquitin incubation with 90 µM CuAc would be required. This 
concentration would greatly increase the noise of our spectrum and likely mask populations of 
ions with very low intensities, needing further clean up steps prior to analysis and so was not 
tested. Similarly linear tetra-ubiqutin (L4UB, 15 µM) was incubated with 15 µM and 45 µM 
CuAc, where 180 µM CuAc would be required for a 3 fold excess with respect to the number of 
ubiquitin domains. 
 4.2.2. Ubiquilin Preparation 
Ubiquilin (WT and P506T) were expressed and purified by collaborators, Magdalenea Ivanova, 
and received in 100 mM ammonium acetate, pH 6.9. Samples were desalted using 6kDA 
MWCO buffer exchange columns (bio-rad), and kept on ice. 
4.2.3. IM-MS – Ubiquitin Aggregation  
Mass spectra were collected on a quadrupole-ion mobility-time-of-flight (TOF) mass 
spectrometer (Synapt G2 HDMS, Waters, Milford, MA, USA) with a nano-electrospray 
ionization (nESI) source. Protein ions were generated using a nESI source and optimized to 
allow transmission of noncovalent protein complexes using electrospray capillaries prepared as 
described previously19. Protein complex ions were generated using an aliquot of the sample (ca. 
3 µL) sprayed from the nESI emitter at a capillary voltage of 1.2– 1.65 kV. The source was 
operated in positive ion mode with the sample cone at 20- 50 V. The bias voltage was 50 V, with 
backing pressure at 2.9- 6.1 mbar and TOF pressure at 1.47 x 10-6 mbar. The travelling-wave IM 
separator was operated at a pressure of approximately 3.0 mbar of nitrogen. Mass spectra were 
calibrated externally using a solution of cesium iodide (100 mg mL-1) and analyzed using 
MassLynx 4.1 and Driftscope 2.0 software (Waters, Milford, MA, USA). Aggregate populations 
were selected in Driftscope, and percentages of the population calculated by dividing the signal 
intensity for the species of interest by the total ion population signal intensity. Averages were 
calculated on one sample using three different nESI needles, and error reported is one standard 
deviation.    
4.2.4. IM-MS – Ubiquilin Aggregation  
Mass spectra were collected as in 4.2.3. Ions were generated with the nESI emitter at a capillary 
voltage of 1.4 kV. The source was operated in positive ion mode with the sample cone at 40 V. 
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The bias voltage was 45 V, with backing pressure at 2.9 mbar and TOF pressure at 1.46 x 10-6 
mbar. The travelling-wave IM separator was operated at a pressure of approximately 3.0 mbar of 
nitrogen. Mass spectra were analyzed using MassLynx 4.1 and Driftscope 2.0 software. 
Aggregate populations were selected in Driftscope, and percentages of the population calculated 
by dividing the signal intensity for the species of interest by the total ion population signal 
intensity.  
The 14+ charge states for both the WT and P506T were selected in a MS/MS experiment for 
CIU fingerprint analysis. Prior to the ion mobility cell, ions were activated in the trap region by 
increasing the voltage applied in this area. By ramping the voltage, and measuring the resulting 
drift time of the unfolded structure at each voltage, a CIU fingerprint can be created. CIU 
fingerprints were collected over a trap collision energy range of 30-150 V, in steps of 5 V. Data 
was analyzed and fingerprints created using home built software, CIUSuite. 
4.3. Results and Discussion 
4.3.1. Ubiquitin in the Presence of Copper 
 Initial studies of 15 µM ubiquitin (Ubq) in 200 
mM ammonium acetate were incubated with 45µM 
copper (II) acetate (CuAc) at 4 °C for 24 h to 
facilitate copper binding and promote aggregation 
while preventing protein degradation. While 
consistent evidence of Ubq aggregation beyond 
dimer formation was not observed under these 
conditions, we did identify a compaction in both 
the monomer and dimer upon copper binding. Each 
copper binding event led to further Ubq 
compaction. It is therefore possible that subsequent 
copper binding events allow for previously 
extended conformations to adopt a more compact, 
and likely more stable, structures in solution, that 
are then broadly conserved in our gas-phase 
Figure 4.1 – Shift in structural populations upon 
copper binding. A) Ubiquitin monomer in the 6+ 
charge state occupies two structural populations in 
the apo state. Each copper binding event shifts the 
populations to a more compact structure, with the 3 
bound copper population being smaller even than 
the most compact form of the apo population. B) 
Upon copper binding to the Ubiquitin 9+ dimer, the 
population shifts to lower drift times.  
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measurements. For example, the apo 6+ monomeric ubiquitin occupies two structural families 
under our conditions, compact and extended (Figure 4.1). Upon binding a single copper, the 
observed population shifts dramatically toward compact conformers; a small amount of the 
extended structure appears as a shoulder. With the addition of further copper to Ubq only 
compact conformational families are observed. It is of note these Cu-bound compact states are 
slightly smaller than the compact conformer family found in the apo state. Although overall 
signal intensity is lower for the dimer when compared with monomeric Ubq signals, we see a 
similar trend for the 9+ dimer, with the shifting of the IM drift time centroid from 5.42 to 5.12 ms 
(a shift of 7.6%). This shift is less substantial than measured for the Ubq monomer (a shift of 
28.9%), with the dimer only occupying a single monomodal conformational family in its apo 
state.  In samples prepared using 
75/25 v/v ammonium acetate/ 
triethyl ammonium acetate (TEAA), 
this phenomenon was not observed. 
Monomeric ubiquitin only occupied 
one structural population, the more 
compact state. The dimer as well 
showed no significant shift in drift 
time upon copper addition.  
While no shift in Ubq IM drift time 
was observed with samples having 
TEAA present, after a 3 h 
incubation on ice with a three-fold 
excess of CuAc, IM-MS data 
revealed that the sample contained 
94.4% (± 2.75%) monomer, 4.0% 
(± 3.2%) dimer, and 1.6% (± 0.5%) 
tetramer. In contrast, control 
samples having no added CuAc 
contained 97.4% (± 1.5%) 
monomer, 2.5% (± 1.3%), and 0.3% 
Figure 4.2 – IM-MS data of copper incubated ubiquitin. Upon 
incubation with 45 µM copper acetate (CuAc), 15 µM monomeric 
ubiquitin (M) aggregates to form increased amounts of dimer (D) and 
tetramer (Q). Increased noise in the sample is from excess CuAc in 
solution. Up to three copper adducts are observed on the M4+ species 
as shown in the MS inset.  
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(± 0.05%) tetramer. This represents a 1.6 fold increase in Ubq dimer concentration, and a 5.3 
fold increase in the Ubq tetramer concentration. Of note, no trimer was observed in either the 
control or the copper incubated samples leading to the conclusion that the tetramer was formed 
through a specific dimer-dimer addition event, and not through non-specific aggregation. IM-MS 
data for these samples are shown in Figure 4.2. In Cu-containing samples, the small amount of 
monomer 5+ observed under non-metal containing conditions is no longer observable, and the 
dimer and tetramer signals have increased in intensity. An increased amount of background noise 
is also observed in Cu-containing spectra, due to salt-cluster associated chemical noise. Our MS 
data supports the addition of up to three Cu ions to Ubq (Figure 4.2 insets), although only one 
copper binding site has been identified at His6820. Zinc and platinum have been shown 
previously to bind three copies to Ubq at His68, Met1, and Lys6 (platinum)/Glu18 (zinc)21, 
although the same studies did not investigate Cu binding.  
While incubation of copper with 
the monomer of Ubq seems to 
increase the Ubq dimer and 
tetramer population substantially, 
we moved to confirm this overall 
result by studying linear tri- and 
tetra-ubiquitin analogs. As for 
single domain constructs of Ubq, 
L3UB measured in 75/25 
ammonium acetate/TEAA 
revealed no evidence of 
compaction upon Cu addition 
(Figure 4.3). After 3 h on ice, 
Cu-free L3UB monomer 
occupies 83.9% of the total IM-MS signal intensity and its dimer (six total Ubq domains) 
occupies 16.1% (σ = 4.44 %). Upon incubation with CuAc incubation at a 1:1 ratio 
(stoichiometric with respect to the number of ubiquitin domains), L3UB monomer makes up 
77.2% of the signal intensity while dimer accounts for 22.8% (σ = 5.3%). This represents an 
Figure 4.3 – Drift Time Analysis of L3UB. The L3UB monomer at a 
7+ charge state occupies a since conformational family. Upon 
addition of a 3x excess of CuAc in 75/25 ammonium acetate/ TEAA. 
No shift in conformational state is observed after 3 h incubation. 
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increase in dimeric state by 1.4 fold, a nearly 4.5 fold greater increase than observed for Cu-
mediated dimerization in monodomain Ubq. (Figure 4.4 Left).  
In contrast to Ubq and L3UB, linear tetra-ubiquitin (L4UB), incubated at 15 µM under 
conditions similar to those described above, we do not observe evidence of Cu-mediated dimer 
or trimer formation by IM-MS (CuAc, 15 µM and 45 µM, Figure 4.4 Right). CuAc 
concentrations of 15 µM and 45 µM represent enough copper to fully occupy 1/4th and 3/4th of 
the ubiquitin domains within L4UB respectively. Large amounts of L4UB ion charge stripping 
Figure 4.4 – IM-MS data showing incubation of polyubiquitin with CuAc. Left) Top – control of linear tri-ubiquitin 
after a 3 h incubation on ice. The majority of signal is tri-ubiquitin (M), with a small amount of its dimer (D). 
Increased background noise is likely attributed to TRIS acetate and Sodium Chloride not entirely removed following 
buffer exchange. Bottom- Incubation with 3x CuAc. Dimer signal increases in intensity by 6.7%. Peak broadening is 
due to copper adduction. Right) Top – control of linear tetra-ubiquitin after 3 h incubation on ice. The majority of 
signal is tetra-ubiquitin (M) with small amounts of its dimer (D). Charge stripping from the M8+ and M7+ is 
observed. Separation of the charge stripped M6+ and D12+ is possible due to varying amounts of adducts shifting the 
mass of the oligomers. The charge stripped species is circled in a solid line. Dimer is circled with a dashed-line. 
Middle and Bottom – Incubation with 15 µM or 45 µM CuAc. Distribution of oligomers does not shift.       
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are observed from the 8+ and 7+ charge states observed by MS (circled with a solid line in the 
right panel of figure 4.4). We also observe a shifted L4UB intact mass in a manner consistent 
with Cu addition to the structure. All three L4UB samples tested (control, 15 µM CuAc, 45 µM 
CuAc) contained protein ion signal identified as 99% monomer, and 1% dimer. The lack of any 
detectable evidence for Cu-mediated protein association in L4UB samples can likely be 
attributed to the lack of sufficient CuAc in solution to drive the oligomerization. The samples 
described here, which include 45 µM CuAc, represent the upper-end of the salt tolerance of nESI 
prior to the onset of significant chemical noise and ion suppression effects.  As such, the data 
shown here cannot be used to differentiate between L4UB aggregation resistance and the need 
for Cu excess to initiate Cu-mediated Ubq-protein association and aggregation. While further 
study will be needed to ascertain to the propensity of L4UB to undergo Cu-mediated 
aggregation, our data clearly show enhanced aggregation and the formation of compact 
structures upon the introduction of Cu for the smaller Ubq and L3UB constructs. 
4.3.2 Ubiquilin2 WT and P506T Mutation 
The ubiquitin-like protein UB2 and its P506T mutant form are studied here using IM-MS in 
order to determine if different dimerzation propensities in vitro can describe their disease 
associations in vivo. In addition, we applied CIU in an effort to detect any differences in stability 
between these two proteoforms. Figure 4.5 shows our IM-MS results, with signals for both 
monomer and dimer distributions for both WT and P506T UB2 constructs detected. WT UB2 is 
dominated by monomeric protein signal, which accounts for 87.1% ± 0.2% of the total IM-MS 
signal observed, and 12.9% dimer. Similarly, IM-MS data for P506T reveals the protein to be 
Figure 4.5 – IM-MS data of Ubiquilin2 proteins. Orange circles label species which are monomeric, while the red 
squares highlight those which are dimers. A) Wild Type Ubiquilin2. B) P506T Ubiquilin2. While more heavily 
adducted than the P506T, the WT UB2 is 87.1% monomer and 12.9% dimer. Mutant P506T is 88.6% monomer, and 
11.4% dimer.   
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primarily monomeric under our conditions (88.6% ± 1.4%) with an amount of dimer (11.4%) 
similar to WT. The monomeric portion of P506T is more than one standard deviation higher than 
that of the WT, indicating a slightly lower propensity for dimerization for the mutant protein in 
this sample preparation. The IM drift times of each species also appear identical, further 
indicating that the WT and P506T are indistinguishable under native conditions. 
While structurally indistinguishable to course-grained measurements of protein fold, such as IM-
MS, if the P506T were to cause structural instability in the detailed tertiary/secondary structure 
of the protein, this may be detectable by CIU. A single charge state (14+) for both the WT and 
P506T was quadruople-selected for CIU fingerprint analysis (Figure 4.6). Both the WT and 
P506T UB2 follow nearly identical unfolding patterns. For both, three main CIU features are 
detected, the first of which is centered at ~15 ms IM drift time, and is stable through 60 V. At 65 
V a new CIU feature appears, with an IM centroid of ~20 ms and remains stable through 95 V. 
For activation voltages between 105 and 150 V a third CIU transition is observed at ~22 ms. A 
difference plot shows areas of significant deviation between CIU data acquired for both UB2 
proteoforms. By computing the root-mean squared deviation at each pixle within the difference 
plot shown in Figure 4.6, we can quantify the difference between the two data set as 3.36. This 
type of small of a value is typical of fingerprints which can be considered identical, as described 
previously22. 
Figure 4.6 – Collision induced unfolding of the 14+ charge state of WT and P506T UB2. A) Unfolding 
fingerprint for WT UB2. Three distinct conformations are observed, one at drift time ~15 ms, one at ~20 ms, and 
one at ~ 21ms. B) Unfolding fingerprint for P506T UB2. Three distinct conformations are again observed, at the 
same drift times as those of the WT. Scale bar ranges from Blue to Red, where the more red the color the more 
intense the signal. C) Difference plot comparing WT and P506T. More blue indicates a more P506T like area, 
more yellow represents more WT. With an RMSD of 3.36, the fingerprints would be considered indistinguishable 
from one another.   
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Taken together, IM-MS and CIU indicates that the two UB2 forms studied here are nearly 
indistinguishable under native conditions (pH ~7) in terms of their structures and stabilities. Both 
protein samples contain approximately 88% monomer and 12% dimer, possess the same gas-
phase stabilities and unfold following the same CIU pathway. Slight variations in the CIU 
stabilities observed can be readily attributed to increased salt adduct stabilization for the WT 
protein, as confirmed by MS23. While differences between the WT and mutant are not observed 
in these initial studies, it does not necessarily contradict previous work. For example, based on 
these proteins differential ability to alter protein degredation, future experiments should certainly 
target in vitro addition of proteosomal subunits to observe differential protein binding 12. In 
addition, the pH and ionic strength dependence of UB2 aggregation was not explored here, and 
since our data strongly indicate similar native states, unfolded forms of UB2 present in solution 
may be a likely source of aggregation propensity detected for these proteins in vivo. 
4.4. Conclusions 
Here we have explored the aggregation propensity of two proteins important to the proteasomal 
degradation pathway, which when impaired can lead to dementia. The first, ubiquitin, signals for 
the degradation of other proteins upon tagging with polyubiquitin, and it has been suggested that 
transition metals may play an important role in this process.  Our studies find that when 
incubated with an excess of copper acetate, copper binding causes a shift to a more compact 
monomeric and dimeric forms of Ubq. When incubated with excess copper in 75/25 v/v 
ammonium acetate/TEAA, dramatically increased amounts of dimer and tetramer are detected. 
The tetramer observed is likely formed through a dimer-dimer addition, as no trimer is detected, 
strongly indicating that this pathway is borne of specific protein-protein binding interfaces. 
L3UB exhibits the same propensity for aggregation when incubated with excess copper, however 
L4UB does not appear to be effected by copper after an incubation for 3 h with sub-
stoichiometric amounts of Cu. It is possible conditions tested here did not reach the 
concentrations of copper required for aggregation of L4UB, and future experiments should aim 
to push the boundaries on Cu addition in nESI-MS in order to fully explore the aggregation of 
larger Ubq constructs. Further, the series of linear polyubiquitins is commercially available up to 
a decameric chain, it would be valuable to see which ubiquitin chain lengths are most susceptible 
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to aggregation in the presence of Cu in order to fully delineate the potential role of these forms in 
neurodegenerative disease etiologies.  
Ubiquilin2, a protein linked with ALS through mutations, shares structural similarities to 
ubiquitin. The N-terminus contains an ubiquitin-like domain, and an ubiquitin-associated domain 
is found on the C-terminus. IM-MS and CIU experiments did not detect any differences between 
the WT and P506T mutations under native conditions in terms of their structures, aggregation 
propensities, or gas-phase stabilities. This however does not mean that the two variants are 
identical to one another broadly speaking. Further experiments which could be probed with IM-
MS would include ubiquilin2-ubiquitin binding experiments, as it is known that the P506T 
mutation impairs the proteasomal degradation pathway. Additionally, it would be interesting to 
probe the interactions of UB2 with copper, to determine if binding occurs to the ubiquitin-like 
domain and facilitates an increased amount of dimerization as observed for the ubiquitin alone.  
In addition, a broader scope of solution conditions, including changes to protein solution pH, 
ionic strength, and temperature, could be used to investigate the aggregation propensity of UB2 
constructs more using IM-MS.  
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Chapter 5. 
Conclusions and Future Directions 
5.1 Conclusions 
The analysis of proteins associated with misfolding diseases is a complex problem. Traditional 
structural biology techniques may struggle with the heterogeneity of samples, low concentrations 
of intermediate species, and the rapid aggregation of these systems. However the combination of 
ion mobility with mass spectrometry allows us to overcome these difficulties. nESI-MS allows 
us to detect low µM concentrations of analyte, and identify oligomeric species with accurate 
mass. Ion mobility assists in additional separation making analysis of complex samples possible. 
As each of the IM and MS experiments take place in the sub second time scale, the capture of 
oligomeric species in the lag phase of aggregation is possible. To date systems such as amyloid 
β1, β2-microglobulin2, islet amyloid polypeptide/ amylin3, α-synuclein4, prion protein5, 
transthyretin6, Alpha 1-antitrypsin7, insulin8, ataxin-39, and tau10 have been studied by IM-MS. 
This has allowed for the elucidation of structural information, aggregation pathways, and 
recently screening of drug molecules proposed to inhibition of aggregation11.  IM-MS has been 
applied to the study of protein aggregation pathways in multiple ways. This includes assessment 
of the conversion of natively-structured monomeric proteins into partially unfolded, disease-
associated forms. It also represents a crucial method for monitoring the transition between 
disordered aggregates and β-structured aggregates. Accurate size measurement allows for the 
building of models which best represent interactions, and IM-MS combined with traditional 
methods such as NMR, X-ray crystallography, TEM, and gel electrophoresis can refine these 
models to the most accurate representation. 
The utilization of IM-MS for the study of amyloid β (chapters 2 & 3) as well as ubiquitin and 
ubiquilin2 (chapter 4) builds upon an already thriving field, contributing analysis of interaction 
partners in the form of neuropeptides, amino acid fragments, and transition metals. We have 
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screened Aβ for interaction with neuropeptides, finding binding events with leucine enkephalin 
and galanin. Additionally, site-directed amino acid substitution revealed the c-terminal 
hydrophobic residues of leucine enkephalin to be critical for the interaction of Aβ:LE. Following 
this discovery we analyzed the interaction of the dipeptide phenylalanine-leucine with Aβ, 
measuring Kd values when incubated with alanine mutations of Aβ to determine a binding 
location. Through these experiments, we find the interaction of Aβ residues Q15 and Y10 to be 
the most preferred binding partners of FL. All Aβ IM-MS experiments were accompanied with 
simulated annealing and the modeling filtered with experimental data to find the most accurate 
representations of the interaction. Modeling predicts this interaction to be mainly through 
hydrogen bonding.  
Turning our attention next to larger aggregation prone proteins, also associated with 
neurophysiological disorders, we studied the aggregation effects of copper on ubiquitin. Mono, 
linear tri- and linear tetra ubiquitin were incubated with copper, revealing an increase in the 
dimeric forms of mono and tri ubiqutin. Incubation with tetra ubiquitin did not reveal further 
aggregation, although this could be due to the copper concentration in solution. Additionally the 
ubiquitin-like Ubiquilin2 WT and P506T mutation were compared for aggregation propensity 
and stability using CIU. No initial differences have been detected in the monomeric stability and 
each have approximately the same percentage of dimer formation.  
5.2. Future Directions 
5.2.1. Screen Interaction of Aβ and a Library of Dipeptides/ Rationally Designed Molecules 
We have characterized the interaction of the dipeptide FL with Aβ through measurement of 
binding strength and site-directed amino acid substitutions. Aβ residues Q15 and Y10 are 
thought to hydrogen bond with FL. Additional experiments on the Aβ:FL system with IM-MS 
alone would not prove to provide additional information. However toxicity studies would 
provide answers to unknown questions.  
In previously published works with Aβ:ligand interactions compactions of the Aβ monomer was 
observed upon ligand binding12, 13. At this time, the compaction cannot be tied with drug 
characteristic or efficacy. In the LE and FL binding events, compaction of the monomer is not 
observed. We hypothesize that this could be due to the flexibility of the LE and FL ligands, 
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whereas previous ligands are much more rigid in structure. Adding double bonds to the backbone 
of FL can increase rigidity. Additionally, the cyclo(FL) dipeptide will be much more rigid than 
the FL dipeptide tested in chapter 3, while still maintaining hydrophobicity and access to side 
chains. If compaction of the monomer is observed upon cyclo(FL) binding or more rigid FL 
structures, we can begin to develop a mechanism regarding ligand characteristics and efficacy in 
preventing oligomer formation with regards to compaction.  
Other modifications to the FL dipeptide which may lend additional information on the mode of 
binding include NH2-FL and FL-Ac to assess the effect of charge and toxicity of the fragment. 
Altering the side chain of phenylalanine, potentially swapping it with a tyrosine residue, can be 
used to test the hydrophobicity effects on binding and additionally test for the regional specificity 
of binding. Lastly, measuring binding affinity of the d-amino acid variant of FL can test the 
effects of stereochemistry on binding, while simultaneously allowing FL to avoid degradation in 
the cell.  
Already IM-MS is proposed as a high throughput tool for the screening of drug libraries13-15. 
Thus, future IM-MS experiments should include screening a library of rationally designed small 
molecules based on FL. These molecules would ideally have properties aimed at increasing 
interaction strengths/specificity, allowing for blood/brain barrier permeability, reducing toxicity, 
and maintaining stabilization of small oligomers/ preventing fibril formation.  
Additionally, FL is one of four hundred dipeptide permutations. The likelihood that LF also 
binds Aβ is quite high. Of interest would be a screen of dipeptide permutations, starting with 
those containing leucine and followed by those containing phenylalanine. Aβ contains two 
phenylalanine residues at locations 19 and 20, which have been demonstrated to be a part of the 
hydrophobic core region responsible for aggregation. Potentially FF could interact here. 
Following a dipeptide screen, rational design using the dipeptide with the highest binding affinity 
could produce additional libraries for testing.  
5.2.2. Molecular Modeling Simulations to Address Solution Equilibrium 
The molecular dynamics simulations presented in chapters 2 and 3, use a two-step approach. The 
first being a docking simulation using Audodock Vina, which holds the protein target rigid, 
while the flexible ligand is docked primarily based on stereochemistry. In these simulations, the 
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starting Aβ structure comes from the aqueous NMR structure retrieved from the protein data 
bank. This is done to reduce computational time and resources. An alternative approach, would 
be to assess the ligand binding in a simulation to mimic solution phase binding. This would 
allow for a much larger pool of starting monomeric structures, and mimic solution phase 
equilibria. These experiments would then be followed with simulated annealing, filtering and 
clustering analysis as described in chapter 3.        
5.2.3. Further Characterization of Ubiquitin and Ubiquitin Like Protein 
The concentrations of copper used in L4UB experiments (45 µM) did not influence the 
aggregation of L4UB.  Future experiments should push the boundaries on copper concentrations 
to see if this is an effect of saturation. To achieve these concentrations, L4UB (15 µM) should be 
incubated with at least 60 µM copper acetate, and up to 180 µM, followed by a buffer exchange 
step to remove excess copper from the solution prior to IM-MS experiments. Further, the series 
of linear polyubiquitins is available up to a decameric chain, it would be of interest to see which 
ubiquitin chain lengths are most susceptible to aggregation in the presence of copper. 
Additionally, the polyubiquitin used in these studies was linear. Ubiquitin linked by lys48 
traditionally signals for degredation, while those linked at lys63 preform non-proteolytic 
functions16. Additional studies could probe the aggregation propensity for those polyubiquitin 
species linked a lys48 in comparison to linear and lys63. 
As demonstrated in chapter 4, ubiquilin2 WT and P506T vary little structurally as analyzed by 
IM-MS on the monomeric level under native conditions. A broader scope of solution conditions, 
including changes to protein solution pH, ionic strength, and temperature could be used to 
investigate differences. It is known that the P506T mutation impairs the proteasomal degradation 
pathway and thus studying the interaction of Ubiquilin2 and ubiquitin through IM-MS is of 
interest. Through our studies with ubiquitin and copper, there is evidence of copper mediated 
aggregation. Incubation of copper with Ubiquilin2 WT and P506T to test their aggregation is 
also of interest.    
5.2.4. Application of IM-MS to the Cancer Associated Protein p53 
While uncontrolled protein aggregation has been implicated in the etiology of many diseases, it 
has only recently been linked with cancer. Recent data indicate that mutant forms of the tumor-
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suppressor protein, p53, undergo an aggregation and recruit WT p53 protein as part of its 
oncogenic activity17. Work moving forward can take the protocols developed in this thesis and 
apply them to cancer-related protein aggregation. Specifically, to perform a step-wise assessment 
of p53 aggregation using both wild type versions of the protein and oncogenic mutants (e.g. 
R273H) in an isolated fashion by IM-MS. These experiments would use MS and tandem MS 
measurements to confirm the stoichiometry of complexes detected beyond the expected tetramer 
and IM measurements to assess the sizes of the complexes. Accurate size information should be 
a priority during this phase, using the simple systems to optimize intact complexes before 
moving on to more complex assemblies. Previous measurements of the intact complex 
demonstrate the feasibility of our approach to this system18-20. Following this, the step-wise 
introduction of various interaction agents should be performed calculating the Kd and protein 
dynamics through subunit exchange. Starting interactions to be tested could include p63, p73, 
GTPBP4 and DNA segments as a control. Preliminary results using the Waters LCT Premier 
mass spectrometer are shown in figure 5.1. Monomeric and p53 are easily identified, with 
Figure 5.1- p53 protein analysis using the LCT Premier Mass Spectrometer. Initial studies using the LCT, show p53 
monomers, and dimers. Sample received were tagged with MBP and a histidine tag. Inset is of the green region. 
Fragmentation of the MBP from the p53 also removes various number of histidine, complicating analysis. Also 
observed were unidentified aggregates at a very high m/z  
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various amounts of tag present. Protein sample preparation and cleaning needs to be optimized 
prior to further analysis. 
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Appendices 
Appendix I. Chapter 2 Supporting Information  
I.I IM-MS analysis of Aβ-galanin and Aβ-bradykinin interactions 
As a follow up to studies of Aβ1-40-LE interactions, presented here are CCS and Kd values for the 
interactions of Aβ1-40 with galanin, and an additional peptide not in the initial screen but shown 
to bind with Aβ: bradykinin. 
Data was collected on the Waters 
Synapt HDMS with the 
instrument parameters given in 
chapter 3. In a mixture of 10 µM 
Aβ1-40: 10 µM neuropeptide the 
1:1 interaction is observed in the 
6+, 5+ and 4+ charge states for 
galanin. In contrast, at the same 
ratios of Aβ:bradykinin both the 
1:1 and 2:1 complexes are 
observed with a greater intensity 
than that of the 1:1 Aβ:galanin. 
The Kd values were calculated 
using the equations and 
methodology provided in chapter 
3. While only one ligand binding 
is observed in equimolar 
mixtures, when incubated in 
excess we see up to 
Figure I-1. Top) 10 µM Aβ incubated with 10 µM galanin. Dark stars 
represent the 1:1 complex at the labeled charge state. Bottom) 10 µM Aβ 
incubated with 10 µM bradykinin. Dark stars represent the 1:1 complex 
and the outlined star represents the Aβ dimer in complex with one 
bradykinin.  
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five bradykinin binding to one Aβ, and up to three binding to the dimer. Single ligand binding is 
observed on oligomers up to the Aβ pentamer (data not shown). Table I-1 highlights CCS data 
collected for both galanin and bradykinin incubations. Table I-2 provides measured Kd values 
taken over a concentration range up to an eight fold excess. Kd values are within magnitude of 
those measured for the Aβ:LE interactions (1:1 ~65-80 µM). This supports further detailed 
analysis of the interaction in the hopes of finding potential biotherapeutics.  
Table I-1. CCS values of Aβ, Galanin, Bradykinin and their complexes. Std Dev is given on replicates and is not 
inclusive of the standard ±3% from instrumental error.  
Aβ 
 Charge State CCS (Å2) Std Dev (Å2)* 
Aβ1-40 2+ 651.4 57.0 
Aβ1-40 3+ 628.2 14.2 
Aβ1-40 4+ 646.7 14.7 
Aβ1-40 4+ 721.6 47.7 
Aβ1-40 5+ 760.3 40.7 
Aβ1-40 5+ 824.3 13.3 
Aβ1-40 Dimer 3+ 835.6  
Aβ1-40 Dimer 3+ 1065.0 4.66 
Aβ1-40 Dimer 4+ 1009.3 5.97 
Aβ1-40 Dimer 5+ 981.0 17.7 
Aβ1-40 Dimer 5+ 1218.5 44.5 
Aβ1-40 Dimer 6+ 1358.1 52.9 
Aβ1-40 Dimer 7+ 1321.5 24.1 
Aβ1-40 Dimer 7+ 1501.7 13.9 
Aβ1-40 Trimer 4+ 1409.9 5.17 
Aβ1-40 Trimer 5+ 1354.1 9.58 
Aβ1-40 Trimer 6+ 1314.4 53.1 
Aβ1-40 Trimer 7+ 1319.3 35.3 
Aβ1-40 Trimer 7+ 1499.6 22.1 
Aβ1-40 Trimer 7+ 1697.0 72.8 
Aβ1-40 Trimer 8+ 1788.3  
Aβ1-40 Trimer 8+ 2084.5  
Aβ1-40 Tetramer 6+ 1646.8 62.2 
Aβ1-40 Tetramer 7+ 1617.7 24.6 
Aβ1-40 Tetramer 8+ 1593.3 99.0 
Aβ1-40 Tetramer 9+ 1928.0 40.8 
Aβ1-40 Pentamer 8+ 1896.0 21.8 
Aβ1-40 Pentamer 9+ 1907.3 51.8 
Bradykinin 
 Charge State CCS (Å2) Std Dev (Å2)* 
Monomer 1+ 266.7 0.78 
Monomer 2+ 248.7 45.5 
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Dimer 2+ 382.3 10.3 
Dimer 3+ 389.1 27.3 
Trimer 2+ 513.0 2.70 
Trimer 3+ 949.7 10.3 
Tetramer 4+ 993.8 0.88 
Galanin 
 Charge State CCS (Å2) Std Dev (Å2)* 
Monomer 2+ 516.8 19.9 
Monomer 3+ 512.8 4.21 
Monomer 4+ 583.8 6.38 
Dimer 3+ 820.4 6.77 
Dimer 4+ 803.6 50.7 
Trimer 5+ 1095.5 9.55 
Tetramer 7+ 1434.3 25.8 
Aβ:Bradykinin 
 Charge State CCS (Å2) Std Dev (Å2)* 
1:1 2+ 782.8 3.28 
1:1 3+ 725.8 5.86 
1:1 4+ 719.1 43.9 
1:1 4+ 911.4 19.0 
1:1 5+ 1000.9 37.0 
1:2 3+ 835.9 2.63 
1:2 4+ 793.4 11.3 
1:2 4+ 998.5 9.56 
1:3 3+ 942.9 2.89 
1:3 4+ 890.1 5.15 
1:3 5+ 861.2 7.32 
1:3 5+ 1201.4 8.44 
1:4 4+ 977.8 0.00 
1:4 5+ 956.8 19.0 
1:4 5+ 1214.5 61.6 
1:5 4+ 1084.5 4.52 
1:5 5+ 1040.2 0.00 
2:1 4+ 1104.6 5.29 
2:1 5+ 1072.7 50.3 
2:1 6+ 1416.8 40.8 
2:2 4+ 1205.8 0.51 
2:2 5+ 1146.8  
2:3 5+ 1239.1 6.01 
2:3 6+ 1239.3 3.99 
3:1 5+ 1212.2 328 
3:1 6+ 1380.7 20.1 
3:1 7+ 1393.9 17.9 
3:2 6+ 1481.7 3.40 
4:1 8+ 1689.3 28.8 
Aβ:Galanin 
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 Charge State CCS (Å2) Std Dev (Å2)* 
1:1 3+ 941.4 1.57 
1:1 4+ 890.6 12.1 
1:1 5+ 943.8 17.4 
1:1 5+ 1189.5 38.4 
1:1 6+ 1288.6 13.6 
1:2 5+ 1131.8 30.1 
1:2 6+ 1208.4 22.0 
2:1 4+ 1301.8  
2:1 5+ 1288.2 54.0 
2:1 6+ 1252.1 29.5 
2:1 7+ 1671.1 69.1 
3:1 6+ 1558.5  
3:1 7+ 1513.2 31.4 
3:1 8+ 1669.0 21.4 
 
Table I-2. Measured Kd values for the Aβ:neuropeptide complexes 
Aβ:Galanin 
 Kd (µM) Std Dev (σ) 
Aβ1-40 Dimer 45.0 50.1 
Aβ1-40 Trimer 46.8 26.4 
1:1 64.5 55.7 
1:2 71.2 34.6 
2:1 31.8 9.14 
3:1 21.9 13.7 
Aβ:Galanin   
 Kd (µM) Std Dev (σ) 
Aβ1-40 Dimer 32.0 25.5 
Aβ1-40 Trimer 16.5 18.8 
Aβ1-40 Tetramer 38.4 21.2 
Aβ1-40 Pentamer 43.3 30.8 
Aβ1-40 Hexamer 8.64 3.26 
1:1 78.1 36.4 
1:2 102.4 34.1 
1:3 102.7 25.5 
1:4 159.2 29.6 
1:5 127.7 43.1 
2:1 140.6 69.6 
2:2 1124.5 994.9 
2:3 18.3 24.9 
3:1 137.7 116.2 
4:1 416.7 208.8 
5:1 95.4 35.5 
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Appendix II. Chapter 3 Supporting Information 
II.I CD Spectroscopy 
WT Aβ1-40 and all its alanine variants were buffer exchanged from ammonium acetate stock 
solution in phosphate buffer using Nest Group G-10 columns and diluted to 25 µM. 
Measurements were performed using a Jasco CD-Spectropolarimeter operated between the 
wavelengths of 180 and 260nm and averaged over 10 scans. CD spectroscopy was used to 
characterize tertiary structure 
of synthesized alanine variants. 
While the majority of alanine 
mutations did not result in a 
change to the tertiary structure, 
Aβ1-40 E22A has characteristic 
β-sheet structure rather than 
random coil. We therefore are 
unable to conclusively 
determine if a change in 
binding affinity with FL is due 
to a structural change or 
because of side-chain specific interactions. 
II.II Aβ1-40 site directed amino acid substitution interaction with LE 
Similarly to the experiments with FL, we performed binding experiments with alanine variants of 
Aβ and LE. Data is shown in figure II-2. D1A, E3A, H6A, Q15A, K16A and V40A have a Kd 
near that of the WT:LE 1:1 interaction (12.1 ± 8.5 µM). However only H6A and V40A have 
values which fall within one standard deviation (18.2 ± 9.65 and 10.3 ± 6.54 µM respectively). 
F4A, R5A, Y10A, H13A, H14A and K28A range in Kd from 55.6 ± 22.2 to 81.3 ± 9.08 µM. 
E11A deviates most significantly at 126 ± 23.6 µM, pointing to E11 as being the most critical 
residue for interaction with LE.     
 
Figure II-1. CD spectra for alanine mutations of Aβ1-40 analyzed. Spectra in 
solid lines have characteristic random coil structure. Those with the dashed 
lines (Aβ1-42 and E22A) have β-sheet structure.  
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Figure II-2. Kd values for the interaction of Aβ:LE. The darkest box represents the 1:1 interaction of 
Aβ:LE, middle 1:2, and the lightest represents the 1:3 interaction. Only measurements with at least 
three replicates are shown with error bars. The yellow box represents the ±1 standard deviation of 
the Aβ1-40:LE 1:1 interaction. 
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Appendix III. Aβ-Small Molecule Interactions 
Aβ:Diphenylpropynone derivative interactions at high concentrations  
Amit S. Pithadia, Akiko Kochi, Molly T. Soper, Michael W. Beck, Zuzhong Liu, Sanghyun Lee, 
Alaina S. DeToma, Brandon T. Ruotolo, and Mi Hee Lim (2012). Reactivity of 
Diphenylpropynone Derivatives Toward Metal-Associated Amyloid-β Species, Inorg. Chem. 51, 
12959-12967  
   
In Alzheimer’s disease (AD), metal-associated amyloid-β (metal-β) species have been suggested 
to be involved in neurotoxicity; however, their role in disease development is still unclear. To 
elucidate this aspect, chemical reagents have been developed as valuable tools for targeting 
metal-Aβ species, modulating the interaction between the metal and Aβ and subsequently 
altering metal-Aβ reactivity. Diphenylpropynone derivatives (DPP1 and DPP2) were designed, 
prepared and characterized, with attention to reactivity. The derivatives are composed of 
structural moieties for metal chelation and Aβ interaction (bifunctionality). The interactions of 
these molecules with Aβ were confirmed by UV-vis, NMR, docking studies and IM-MS. The 
effects of these bifunctional molecules on the control of in vitro metal-free and metal induced Aβ 
aggregation were investigated and monitored by gel electrophoresis and TEM.  Both DPP1 and 
DPP2 showed reactivity toward metal-Aβ species over metal-free Aβ species to different extents. 
In particular, DPP2, which contains a dimethylamino group, exhibited greater reactivity with 
metal-Aβ species than DPP1, suggesting a structure-reactivity relationship. In depth discussion 
of the interactions as observed with IM-MS is presented here. 
III.I Materials and Methods 
All reagents were purchased from commercial suppliers and used as received unless otherwise 
stated. The compound, 3-phenyl-1-(pyridine-2-yl)prop-2-yn-1-one (DPP1), was prepared 
following previously reported methods1-3. DPP2 was synthesized by slight modifications to a 
previously reported procedure3. Aβ1-40 was purchased from AnaSpec (Fremont, CA). 
The interaction of DPP1 or DPP2 with Aβ1-40 was investigated by nESI-MS on a Waters Synapt 
G2 ion mobility- mass spectrometer (Milford, MA). Samples were prepared by mixing stock 
solutions of DPP1 or DPP2 (prepared in DMSO) and Aβ1-40 (dissolved in 100 mM ammonium 
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acetate, pH 6.8) to generate desired final concentrations of the peptide and compound. Mixtures 
were incubated on ice or at room temperature for 2 or 4 h, respectively, and then analyzed. To 
produce protein complex ions, an aliquot of the sample (ca. 5 µL) was sprayed from the nESI 
emitter using a capillary voltage of 1.4 kV, with the source operating in positive ion mode and 
the sample cone operated at 50 V. To normalize nESI-MS data for nonspecific and electrospray 
artifact interactions that could occur at high concentrations, data were acquired for Aβ1-40 
samples containing thioflavin-T (ThT), a compound known to have no affinity for soluble forms 
of the Aβ1-40 peptide4, under identical concentration conditions as our DPP1 and DPP2 
experiments. Any ThT binding observed was assumed to be due to either nonspecific binding or 
the electrospray process, and subtracted from the intensities of the DPP1 and DPP2 interactions 
observed5. This procedure was performed over a broad range of concentrations. The mass spectra 
were acquired with the following settings and tuned to avoid ion activation and to preserve 
noncovalent protein-ligand complexes6: backing pressure, 7.3 mbar; IMS pressure reading, 3.09 
mbar; ToF analyzer pressure, 1.14 x 10-6 mbar.  
III.II Aβ Interaction with DPP1 and DPP2 Studied by MS 
The interaction of DPP1 and DPP2 with Aβ1-40 in the absence of metal ions was probed by ESI-
MS, tuned to preserve noncovalent protein-ligand interactions6. At low Aβ1-40 concentrations (10 
µM), a small signal corresponding to the interaction between DPP2 (30 µM) and the Aβ1-40 
monomer in the 3+ charge state could be detected, whereas no interaction between DPP1 (60 
µM) and the peptide was observed under these conditions (Figure III-1).  
Figure III-1. Right) Interactions of DPP1 (60 µM) and Left) DPP2 (30 µM) with Aβ1-40 (10 µM) 
determined by nESI-MS. Binding of DPP2 to Aβ monomer was observed at the 3+ charge state. 
Incubation time = 2 h on ice.   
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At high concentrations of the peptide 
(100 µM) and compounds (600 µM), 
both DPP1 and DPP2 interacted with 
Aβ1-40 species to different extents 
(Figure III-2). Data for DPP1 indicated 
that the molecule interacted broadly 
with Aβ1-40 monomers and oligomers in 
1:1, 2:1, and 3:1 Aβ1-40 to ligand ratios. 
In the case of DPP2, a stronger 
preference toward larger Aβ1-40 
oligomers was shown, but with similar 
stoichiometries as DPP1. The total 
bound intensities recorded from MS 
data, and those from individual 
oligomeric species are shown in Figure 
III-2 and Table III-1. The intensities 
shown were normalized for both 
nonspecific interactions and a artifactual 
complexes formed during the 
electrospray process using Aβ1-40:ThT 
binding data as a control, and ion 
mobility separation was used to separate 
oligomers that overlapped in m/z6-8. From these data, it was clear that, at high concentrations, a 
higher proportion of DPP1 was bound to Aβ1-40 species than DPP2, but that both could be 
classified as having a weak Aβ1-40 affinity in solution (low mM Kd). Therefore, a weak Aβ1-
40/compound interaction was captured by MS. Normalized intensity data suggest that DPP2 
binding was almost exclusively driven through Aβ1-40 multimer interactions. Overall, our MS 
results suggest that although both compounds could interact with Aβ1-40 species at high 
concentrations, DPP2 was able to bind Aβ1-40 species at both low and high concentrations. 
  
Figure III-2. Interactions of DPP1 and DPP2 with Aβ1-40. MS 
data for the complexes of Aβ1-40 and A) DPP1 and B) DPP2. 
([Aβ] = 100 µM; [compound] = 600 µM; M= monomer, D = 
dimer, T = trimer). Many binding stoichiometries were detected, 
including 1:1 (star), 2:1 (square), and 3:1 (triangle). C) histogram 
showing the total bound MS signal intensity, normalized for 
nonspecific interactions and ESI-MS artifacts, for each binding 
stoichiometry observed in A) and B).   
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Table III-1. Raw MS signal intensity data for the interaction of DPP1 or DPP2 with Aβ1-40 species.  
DPP1 
 Avg Unbound Signal 
Avg Bound 
Signal 
Total Signal for 
Bound/Unbound % Bound 
% ThT 
Bound 
Normalized % 
Bound 
Monomer 20966.82 4336.01 25302.84 17.14 0.26 16.88 
Dimer 2527.24 1386.40 3913.64 35.42 0.00 35.42 
Trimer 444.05 450.33 894.38 50.35 5.71 44.64 
All Oligomers 23938.12 6172.74 30110.86 20.50 0.43 20.07 
DPP2 
 Avg Unbound Signal 
Avg Bound 
Signal 
Total Signal for 
Bound/Unbound % Bound 
% ThT 
Bound 
Normalized % 
Bound 
Monomer 4386.14 230.22 4616.37 4.89 0.26 4.63 
Dimer 929.44 251.82 1181.26 20.37 0.00 20.37 
Trimer 520.65 238.58 759.23 29.71 5.71 24.00 
All Oligomers 5836.23 720.63 6556.86 10.60 0.43 10.18 
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Appendix IV. Aβ preparation. 
IV.I Steps for preparation.  
These steps should result in consistent stocks, with a mostly monomeric starting species. Dimers 
and occasionally timers will be observed in low abundance. This preparation should be used for 
all WT and mutant Aβ stocks. 
I) Dissolve 1 mg Aβ peptide in 200 μL 1% (v/v) Ammonium Hydroxide. Vortex if 
necessary. 
II)  Add 1300 μL 100 mM ammonium acetate, pH 6.9 (or pH 7.4 depending on 
requirements). 
III) Inject sample into Slide-A-Lyzer Dialysis Cassete (2K MWCO, 3 mL volume, 
Thermo Scientific)  
IV) Add 100 mM ammonium acetate to fill to volume of cassette capacity.  
V) Dialyze in 100 mM ammonium acetate for 3.5 to 4 hours. 
VI) Refresh buffer. Dialyze 3.5 to 4 hours. 
VII) Refresh buffer. Continue dialysis overnight for a total of ~24 h. 
VIII) Remove sample from dialysis cassette. 
IX) Lyophilize (freeze dry) overnight. 
X) Dissolve lyophilized stock in 200 μL 1% ammonium hydroxide. Vortex if 
necessary 
XI) Add 1300 μL 100 mM ammonium acetate, pH 6.9 (or pH 7.4 depending on 
requirements). 
XII) Measure absorbance at 280 nm in triplicate to determine concentration.  
ε = 1490 M-1cm-1 for WT Aβ 
XIII) Aliquot and freeze in liquid nitrogen (store at -80 °C) 
  
 
